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ABSTRACT 
 
 
 
Identification of a Mutation in COL4A5 Causative for X-linked Alport Syndrome in the 
Domestic Dog and Analysis of Gene Expression in the Kidneys of Affected and 
Nonaffected Siblings. (December 2003) 
Melissa Luanne Cox, B.Sc., Dalhousie University 
Chair of Advisory Committee:  Dr. Keith E. Murphy 
 
 
 
 
The domestic dog, Canis lupus familiaris, plays many roles in the lives of 
humans. Additionally, the dog is recognized for its potential as a model for many human 
hereditary diseases. Thus, the genetics and genomics of the dog are being studied 
extensively in order to facilitate its use as a model, as well as to help the dog for its own 
sake. As part of this research effort, our laboratory has added type I markers (i.e., the 
acidic and basic keratins, c-kit, type I and IV collagens, and the gene encoding 
uromodulin) to the emerging map of the canine genome. The mapping of genes, 
particularly those in large gene families such as the collagens, is valuable because it 
rapidly increases the density of gene loci on the map and provides insight regarding 
conservation of synteny between the dog and other mammals. The major focus of work 
reported here is the genetics of X-linked Alport syndrome (XLAS), a terminal renal 
disease that affects the human and the dog. The disease results from mutations in 
COL4A5, a type IV collagen gene. Reported here are the 1) sequencing and mapping of 
the canine cDNA encoding uromodulin, 2) mapping of the type I and type IV collagen 
 iv
genes, 3) sequencing of the full-length cDNA of canine COL4A5, 4) identification of a 
10 bp deletion in COL4A5, causative for XLAS in our colony of mixed breed dogs, 5) 
development of a genetic test for identification of affected and carrier dogs in the colony 
and 6) assessment of gene expression in the kidneys of normal and XLAS-dogs. This 
assessment was performed using a canine-specific oligonucleotide microarray. XLAS 
dogs demonstrated up-regulation of many genes involved in extracellular matrix 
reorganization, cell structure, and immune response, as expected in a glomerulopathy 
with tubulointerstitial nephritis. Trends were verified by quantitative RT-PCR. A review 
of the current status of canine genetics research, and current understanding of hereditary 
diseases in the dog, concludes this dissertation. 
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CHAPTER I 
INTRODUCTION 
 
Genetics and genomics of the dog 
The domestic dog, Canis lupus familiaris, has contributed to our lives in many 
ways but most importantly as a companion. The dog is a subspecies of wolf, Canis 
lupus, and medical surveillance and treatment of it are second only to that of the human. 
Dogs have been bred for many purposes, with goals of both practicality and aesthetics. 
More specifically, nonrandom breeding programs have resulted in the creation of types 
and finally “purebreeds”, most of which were developed in the past 250 years (Ostrander 
and Giniger 1997). In order to fix desirable traits, breeders have practiced various levels 
of inbreeding. Founder effects, population bottlenecks and surges in breed popularity 
have also placed intense selective pressure upon the dog, resulting in the emergence of 
more than 450 known hereditary diseases (OMIA 2003).  
The major problem for breeders of purebred dogs is that the majority (Ostrander 
and Kruglyak 2000) of hereditary diseases in the dog are inherited in an autosomal 
recessive manner. Thus, it is not possible to prevent the production of affected animals 
without knowing the carrier status of the parents. Additionally, late-onset autosomal 
dominant diseases are also difficult to prevent because affected dogs are often used for 
breeding before symptoms of such diseases become evident. To improve the quality of  
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life for dogs and the peace of mind of their owners, it is essential to develop genetic tests 
that identify carriers and those dogs destined to be affected by hereditary diseases. 
Understanding the genetic bases of the myriad of canine hereditary diseases may also 
lead to preemptive treatments or better management of clinical disease. 
Approximately half of the aforementioned 450 hereditary canine diseases are 
also found in the human and have very similar clinical presentations. Importantly, the 
human and canine diseases are most often caused by mutations in the same genes 
(Ostrander and Giniger 1997; OMIA 2003). Therefore, due to large litter sizes, short 
generation times, reduced genetic heterogeneity and well documented inbred lines, the 
dog serves as an ideal natural model for study of the genetics governing various human 
hereditary diseases as well as other inherited traits. It is not surprising, then, that the dog 
is being utilized to understand human genetics, inheritance of complex traits and in gene 
therapy regimens (Bartlett et al. 1996; Knapp and Waters 1997; Venta et al. 2000; 
Acland et al. 2001; Hungs et al. 2001; Lou et al. 2003). Of course, a great advantage that 
allows for the dog to be used to full potential in development of treatments and therapies 
applicable to the human is our extensive knowledge of canine medicine. Furthermore, 
because dogs usually live in the same environment as humans, external factors that may 
affect expression of hereditary diseases in both animals are the same. Even so, the cost 
of maintaining colonies of dogs is often prohibitive. However, collaborations among 
breeders, clubs and geneticists often allows for the collection of pedigrees and 
appropriate samples (blood, DNA, biopsies, etc.) for the study of these diseases without 
having to maintain such colonies. 
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Sequencing and mapping of canine gene loci  
During the last decade, the major impediment to using the dog as a model has 
been the paucity of information about the canine genome and the lack of resources 
necessary to study canine genetics. The 38 small, acrocentric chromosomes of the dog 
complicated the standardization of the canine karyotype and prevented genomic 
mapping efforts typical of other model organisms such as the mouse. In 1999, the 
consensus karyotype was established with the use of canine whole chromosome-specific 
fluorescence in situ hybridization (FISH) paint probes (Breen et al. 1999a; Breen et al. 
1999b). 
While FISH is certainly a valuable tool, a critical step in the study of the canine 
genome was the construction of a radiation hybrid (RH) cell panel. To this end, a 5000-
rad RH panel was constructed from canine fibroblasts and fused with HTK3-1 Chinese 
hamster cells (Vignaux et al. 1999). The most recent version of this panel, RHDF5000-2, 
is comprised of 118 cell lines on which 3270 markers have been mapped (Guyon et al. 
2003). The integration of cytogenetic data and meiotic linkage data has resulted in a map 
of the canine genome with 1-Mb resolution (Guyon et al. 2003).  
An important advance in canine genomics has been the identification and 
characterization of microsatellite markers. Briefly, characterization of 150 microsatellite 
markers and 30 linkage groups provided the framework for a linkage map that was 
rapidly expanded upon in recent years (Mellersh et al. 1997). These markers are the 
foundation on which early maps were built and the current version of the canine linkage 
map has 1596 microsatellite markers distributed across all chromosomes (Guyon et al. 
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2003). The utility of microsatellites is further emphasized by the fact that these markers 
can be used to assess linkage of markers with hereditary diseases (Flinter et al. 1989; 
Ron et al. 1994; Tanaka et al. 2003). However, in order for this to be effective, markers 
used in linkage analysis must be selected based on information content. Therefore, using 
the integrated linkage-radiation hybrid map developed in 1999, 172 microsatellite 
markers were selected and characterized for use in whole genome screens. This subset of 
markers provides 10 cM coverage of the canine genome and is termed the Minimal 
Screening Set -1 (MSS-1) (Richman et al. 2001). The MSS-1 was enhanced by 
multiplexing that streamlines screens of the genome (Cargill et al. 2002). Finally, 
construction of the most recent version of the canine map (Guyon et al. 2003) made 
possible the identification of a more comprehensive screening set, the MSS-2. The MSS-
2 is comprised of 327 microsatellites providing 5 cM coverage and has an average 
spacing of 9 Mb (Guyon et al. 2003). 
 The importance of the dog as a model for study of human hereditary diseases is 
evidenced by the decision of the National Human Genome Research Institute (NHGRI) 
(http://www.genome.gov/11008069) to fully support sequencing the genomes of several 
breeds. Celera conducted the first large scale sequencing effort for the dog using a male 
Standard Poodle; this 1X coverage sequence is only available through collaborations 
with The Institute for Genome Research (TIGR). The need for a higher resolution 
sequence was recognized by NHGRI and sequencing of the dog that will yield a final 
product with 6.5X coverage will likely be completed in January 2004. The dog being 
sequenced is a female Boxer named Tasha. Other breeds to be sequenced are yet to be 
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determined but the Beagle, Doberman Pinscher and the gray wolf will be sequenced with 
final resolution of approximately 1X. All sequencing is being done using a whole 
genome shotgun approach at The Whitehead Institute. Data are made available on a 
daily basis through the deposition of trace sequences into Ensembl 
(ftp://ftp.ensembl.org/pub/traces/canis_familiaris/) and the NCBI Trace Archive 
(http://www.ncbi.nlm.nih.gov/Traces/trace). 
Although the sequence of the dog will soon be available, mapping is still an 
important endeavor because markers are necessary to both localize and provide 
“landmarks” for sequence information. Additionally, mapping is important in 
comparative genomics for establishing regions of conserved synteny. As part of the 
effort to supplement mapping of the canine genome, our laboratory maps large gene 
families, particularly those encoding structural proteins of medical relevance. For 
example, the acidic and basic keratins (Miller et al. 1999; Miller et al. 2001) are 
implicated in various skin diseases, and the type I and type IV collagens are known to be 
involved in diseases of the connective tissue and facia. We are also interested in genes 
expressed in an organ-specific fashion that may potentially play roles in diseases of the 
human and dog. The uromodulin gene and the collagen gene superfamily are of current 
interest to us.  
 
Biology of uromodulin 
Uromodulin, also known as “Tamm-Horsfall glycoprotein” is a renal-specific, 
GPI-anchored cell membrane protein, and is the most abundant protein found in normal 
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urine.  A definitive function for uromodulin has not yet been established but recently it 
was discovered that mutations in the gene are causitive for two hereditary human renal 
diseases: medullary cystic kidney disease and familial juvenile hyperuricemic 
nephropathy (Hart et al. 2002). These diseases are transmitted in autosomal dominant 
fashion and are typified by juvenile onset of hyperuricemia, gout, and progressive renal 
failure.  
 
The collagen genes  
The superfamily of collagen genes consists of more than 40 genes, grouped into 
27 subfamilies. These proteins are the major components of connective tissues, 
extracellular matrix, and basement membranes in the body. Fibrous polypeptides, such 
as the type I and type IV collagens, coil into left-handed helices, and three such chains, 
in different combinations, wrap around each other to form a right-handed super-helix. 
The triple-helical domains intertwine and supercoil and the proteins usually form fibers 
or networks. Collagens are characterized by Gly-X-Y repeats in the collagenous 
domains. The presence of glycine (the smallest amino acid) at every third amino acid 
position is essential for the tight folding pattern to occur. Proline and hydroxyproline are 
often found in the X and Y positions, respectively. Globular sequences may interrupt the 
collageneous domains and confer greater flexibility. A short, non-collagenous domain 
(7S domain) exists at the amino terminus, while a long globular domain (NC1 domain) 
of approximately 230 amino acid residues exists at the carboxyl terminus. These non-
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collagenous domains contain conserved cysteine residues that are critical for disulfide 
bonding (Pihlajaniemi et al. 1990).  
There are two type I collagens, COL1A1 and COL1A2. These are found in bone, 
skin, and tendons, and mutations in each are responsible for forms of Ehlers Danlos 
syndrome and Osteogenesis imperfecta. There are six known type IV collagens, 
COL4A1-COL4A6, which form lattices upon which other basement membrane 
components are assembled. No known diseases are caused by mutations in the COL4A1 
or COL4A2 genes. In contrast, mutations in the other type IV collagen genes are 
causative for several diseases, including Alport syndrome (AS) which is categorized as 
X-linked Alport syndrome (XLAS) (Hudson et al. 2003) and autosomal recessive Alport 
syndrome (ARAS) (Hudson et al. 2003). Autosomal dominant forms of the disease have 
been described, but the genetic cause is unknown (Hood et al. 1995; Ciccarese et al. 
2001; Longo et al. 2002). Mutations in COL4A4 causative for ARAS may also be 
responsible for Benign Familial Hematuria (Thin Basement Membrane Disease) 
(Lemmink et al. 1996). In addition to the mutations in COL4A5 that cause X-linked 
dominant AS, contiguous and extensive gene deletions, typified by deletions of the 5' 
regions of COL4A5 and COL4A6 (including up to exon 3 of COL4A6), result in diffuse 
leiomyomatosis which is often seen in conjunction with AS (Zhou et al. 1993; Heidet et 
al. 1997). Although COL4A3 has not been implicated in a disease other than ARAS, it is 
involved in Goodpasture syndrome, an autoimmune disorder in which the globular NC1 
domain of COL4A3 is an epitope for autoantibodies  (Turner et al. 1992). 
 
 8
Clinical aspects of Alport syndrome 
 Alport syndrome is a heterogeneous group of hereditary glomerular diseases that 
lead to progressive renal failure. While rare, AS is an important cause of human end 
stage renal disease (ESRD) worldwide. Information regarding the prevalence of AS, as 
well as other monogenic diseases that cause ESRD, is sparse (Levy and Feingold 2000). 
One recent estimate, based on data from Finland, was that the birth prevalence of AS is 1 
in 53,000 live births (Pajari et al. 1996). Such data likely apply to large populations of 
European origin, but data regarding large populations of other geographic origins are 
lacking (Levy and Feingold 2000). In Europe, AS accounts for 1.5% of children starting 
renal replacement therapy (Loirat et al. 1994). In the United States, AS affects about 3% 
of children with chronic renal failure and about 0.3% of adults with ESRD (USRDA 
1996).  
Although the phenotypic spectrum of AS is diverse, the underlying structural 
abnormalities that are common to all forms of the disease are defective basement 
membranes in various organs, hematuria, and proteinuria. In the kidney, the alterations 
in the structure of glomerular basement membranes (GBM) are associated with 
progressive changes in glomerular function. Permselectivity of the glomerular filtration 
barrier becomes altered and proteinuria (the abnormal loss of protein in the urine) 
ensues. Progressive glomerular injury and scarring (glomerulosclerosis) occur such that 
individual glomeruli eventually cease filtration entirely. Progressive reduction of 
glomerular filtration rate (GFR) eventually leads to renal failure. These sequential 
glomerular changes are accompanied by progressive injury, inflammation and scarring 
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that affects the tubules and interstitium of the renal cortex. Thus, although the 
nephropathy associated with AS is initiated by molecular defects in the GBM, eventually 
the entire kidney is affected by the progressive structural damage and functional 
deterioration that lead to ESRD. 
While it is true that different modes of genetic transmission exist for AS, the 
majority (more than 95%) of cases are either XLAS or ARAS. Approximately 85% of 
human AS cases are X-linked. In males with XLAS, the clinical symptoms generally 
begin with microscopic hematuria starting at around five years of age, followed by 
sensorineural deafness (Cohen et al. 1961; Crawfurd and Toghill 1968), hypertension by 
the mid-teens, and a deterioration of renal function, culminating in chronic renal failure 
in the mid-twenties (McCarthy and Maino 2000). Carrier females, due to lyonization, are 
mosaics. Since XLAS is a dominant disease, females usually show microscopic 
hematuria in their early twenties, and subsequent hypertension, but the remarkable 
reserve capacity of the kidney ensures that only 5-10% of carriers progress to chronic 
renal failure (McCarthy and Maino 2000). In addition to the aforementioned problems 
arising from AS, patients may also exhibit ocular defects (Colville and Savige 1997). At 
present, the only treatment options available for patients with AS-induced chronic renal 
failure (CRF) are dialysis and eventual renal transplantation.  
 
Cell biology and genetics of Alport syndrome 
 Renal function is impaired in XLAS and ARAS because the GBM lacks the 
crucial type IV collagen network containing COL4A3, COL4A4, and COL4A5 that is 
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required for long-term stability of the GBM. This network is an assembly of 
heterotrimeric proteins containing each of these three peptides, and absence of one any 
of the three chains precludes formation of the network. Thus, a mutation in any of the 
genes encoding COL4A3, COL4A4, or COL4A5 results in a dominant negative effect. 
Consequently, the integrity of the GBM is compromised and chronic progressive renal 
disease inevitably ensues. XLAS and ARAS have identical clinical manifestations, and 
are characterized by the absence of COL4A3, COL4A4, and COL4A5 in the GBM of 
affected individuals. Genetic causes of the rare autosomal dominant forms of AS are 
obscure. XLAS results from mutations in COL4A5 (Martin et al. 1998) that was mapped 
to Xq22.3 (Hostikka et al. 1990). ARAS results from mutations in either the COL4A3 or 
COL4A4 genes, which are found on chromosome 2 in humans.  
  Interestingly, COL4A3, COL4A4, and COL4A5 are not part of the GBM early in 
development. COL4A1 and COL4A2 initially predominate in the GBM of immature 
glomeruli, and are replaced quantitatively by COL4A3, COL4A4 and COL4A5 as 
glomerular maturation continues. Thus, glomerular development normally involves an 
isotypic switch from the fetal-type COL4A1/COL4A2 GBM network to the adult-type 
COL4A3/COL4A4/COL4A5 GBM network in mature glomeruli (Miner 1998). The 
COL4A3, COL4A4, and COL4A5 chains have more cysteine residues in their triple 
helical and 7S regions, as compared to COL4A1 and COL4A2. This increases disulfide 
bonding and increases resistance to endopeptidases as compared to COL4A1 and 
COL4A2 (Kalluri et al. 1997). In subjects with XLAS, however, the normal isotypic 
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switch cannot occur because of the absence of functional COL4A5. As a consequence, 
the GBM eventually becomes “leaky” because of this abnormality.  
Although type IV collagen abnormalities have been identified as the inciting 
cause of AS, important aspects of AS remain ill defined (Kashtan 2002). For example, 
the complete absence of the GBM COL4A3/COL4A4/COL4A5 network does not impair 
glomerular development nor does it cause glomerular function to be abnormal early in 
life (Harvey et al. 1998). Also, mechanisms linking the type IV collagen defects to 
subsequent events, beginning with GBM changes and culminating with ESRD, are 
incompletely understood (Kashtan 2002). Moreover, treatments of proven efficacy to 
retard or halt progression of renal failure in AS patients have not been developed 
(Cosgrove et al. 1996; Lu 1999; Miner and Sanes 1996). 
 
Canine Alport syndrome 
The dog is the only naturally occurring model for XLAS and two models are 
under study: the Samoyed (Zheng et al. 1994) and a mixed breed (Lees et al. 1999). The 
progression of AS in these dogs from birth to ESRD is very similar to that observed in 
humans. However, unlike in human beings with XLAS who may also develop 
sensorineural deafness and ocular abnormalities, only renal disease has been noted in 
spontaneous canine models of XLAS. In dogs with XLAS, ultrastructure of the GBM is 
completely normal at birth despite lack of the normal developmental isotypic switch and 
complete absence of the COL4A3/COL4A4/COL4A5 network in the GBM (Harvey et 
al. 1998). Renal biopsies of Samoyeds with XLAS examined at one month of age, when 
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the isotypic switch would usually take place, exhibit bilaminar splitting of the GBM 
(Harvey et al. 1998). This suggests that COL4A1 and COL4A2 are necessary and 
sufficient for normal GBM development, while the COL4A3, COL4A4, and COL4A5 
network is necessary for GBM stability and maintenance of glomerular function (Harvey 
et al. 1998).  
In 1993, Dr. George E. Lees of Texas A&M University examined several mixed 
breed dogs from a single family in which some adolescent males developed CRF. Dogs 
in this family exhibited the clinical, immunohistochemical, and pathological 
characteristics typical of AS. The structural and functional abnormalities of their GBM, 
along with an X-linked dominant mode of inheritance, indicated the dogs had a disease 
analogous to human XLAS (Lees et al. 1999). As expected, XLAS in the dog is 
characterized by absence of COL4A5 in the GBM as determined by 
immunofluorescence using a monoclonal antibody against the NC1 region of the 
polypeptide. Immunofluroescence microscopy also confirmed absence of COL4A3 and 
COL4A4 in the GBM of affected dogs, as is observed in affected humans (Lees et al. 
1999).  
 To further characterize the clinical and genetic aspects of the disease, Dr. Lees 
established a breeding colony of carrier females at TAMU-CVM (Lees et al. 1999). 
Normal female hound dogs were artificially inseminated with the semen of two affected 
male dogs that had lived to puberty. Carrier female progeny of these matings were raised 
and subsequently bred to a normal Labrador Retriever to produce additional affected 
 13
males, carrier females and normal dogs (males and females). Dogs in this colony are 
termed Navasota (NAV) dogs. 
Affected male NAV dogs typically develop proteinuria between four and six 
months of age. Chronic progressive renal disease associated with glomerular and 
tubulointerstitial lesions causes a reduction in GFR between 6 and 9 months of age. 
ESRD occurs at an average age of 11 months (Lees et al. 1999). The reserve capacity of 
the kidney often masks the signs and symptoms of CRF until late in the disease process 
but maintenance of the colony of dogs provides a model that allows study of the earliest 
processes leading to CRF. The dog is especially useful in this regard because its large 
size, as compared with many traditional (e.g., rodent) animal models, more closely 
mimics the physiological and environmental stresses on the human kidney. However, to 
use the NAV dog as a model, identification and characterization of a mutation in 
COL4A5 that is causative for XLAS as well as an efficient way to diagnose dogs at the 
genetic level, thereby obviating the need for biopsy, is necessary. 
 
Specific objectives 
There were three objectives of this project: 1) to supplement the map of the 
canine genome by adding gene loci to the integrated meiotic linkage-radiation hybrid 
map, 2) to identify the mutation causative for XLAS in the NAV dog and develop a 
genetic test to identify carriers and at-risk dogs and 3) to generate renal gene expression 
profiles of affected and non-affected NAV dogs in order to understand the genetic 
changes that accompany AS and generalized ESRD. The first two goals are 
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straightforward but the third is far more complex. To accomplish the third objective, 
probing of a canine oligonucleotide microarray and quantitative real time PCR (Q-RT-
PCR) are necessary. These experiments are imperative for evaluation of gene expression 
in kidneys with ESRD. A canine microarray (Affymetrix GeneChips) has been 
constructed and purchased by collaborators for our use. The six type IV collagens are 
represented on this array, as are many other canine genes of potential interest including 
those encoding other components of the GBM.   
 
Summary 
Mapping of the uromodulin gene and the type I and type IV collagens added 
gene loci to the map of the canine genome. Secondly, by sequencing the entire coding 
region of COL4A5, a mutation causative for XLAS in the NAV dog was identified. 
Subsequent to identification of the mutation, a genetic test was developed to identify 
carriers and dogs destined to develop XLAS. Finally, analysis of gene expression using a 
canine oligonucleotide microarray has revealed differential expression of genes in 
affected NAV dogs as compared to normal NAV dogs.  
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CHAPTER II 
RADIATION HYBRID MAPPING OF THE CANINE TYPE I AND TYPE IV 
COLLAGEN GENE SUBFAMILIES* 
 
Overview 
 We are interested in the collagen gene super-family and its involvement in 
hereditary diseases of the human and domestic dog. Presented here are radiation hybrid 
mapping of the type I and type IV collagen gene subfamilies on the most recent version 
of the canine map. The COL1A1 gene was mapped to chromosome (Chr) 9, COL1A2 
was mapped to Chr 14, COL4A1 and COL4A2 were mapped to Chr 22 and COL4A3 and 
COL4A4 were mapped to Chr 25. The COL4A5 and COL4A6 genes, while linked to one 
another, are not linked in the present version of the canine map but likely are present on 
the X Chr. These data provide insight into molecular evolution of these subfamilies and 
increase the number of mapped genes in discrete regions of the canine genome. 
 
Introduction  
 The super-family of collagen genes features 31 genes grouped into 19 
subfamilies. Collagens are the major components of connective tissues, the extracellular  
matrix and basement membranes (Table 1). Types I-IV represent fibrous collagens while  
__________________ 
*Reprinted with permission from Lowe JK, Guyon R, Cox ML, Mitchell DC, Lonkar AL et al. (2003) 
Radiation hybrid mapping of the canine type I and type IV collagen gene subfamilies. Funct Integr 
Genomics 3, 112-116   
Copyright Springer-Verlag GmbH & Co.KG 
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all the others are non-fibril forming. The fibrous collagens coil into left-handed helices, 
and three such chains, in different combinations, wrap around each other to form a right-
handed super-helix. The triple-helical domains intertwine and supercoil; the proteins 
usually form fibers or networks. The importance of these networks is evident since 
mutations in genes encoding many of the collagens are causative for several human 
hereditary diseases (Table 1). Some of these diseases (e.g., Alport syndrome and Ehlers 
Danlos syndrome) have also been described in the dog and result from mutations in the 
canine collagen orthologs (Freeman et al. 1987; Zheng et al. 1994; Rodriguez et al. 
1996; Lees et al. 1999). 
 
Table 1. Type I and IV collagen gene subfamilies. 
Gene Location 
(human) 
Location 
(mouse) 
Location 
(dog) 
Tissue-specific 
expression 
Examples of 
associated diseases 
COL1A1 HSA 
17q21.3-
q22.1 
MMU 11 CFA9 Bone, skin, tendon Ehlers Danlos syndrome 
COL1A2 HSA 
7q22.1 
MMU 6 CFA18 Bone, skin, tendon Osteogenesis imperfecta  
Ehlers Danlos syndrome 
COL4A1 HSA13q34 MMU 8 CFA22 All basement membranes No known diseases 
COL4A2 HSA13q34 MMU 8 CFA22 All basement membranes No known diseases 
COL4A3 HSA 
2q35-q37 
MMU 1 CFA25 Basement membranes of 
kidney, eye, cochlea, 
lung, brain 
Goodpasture syndrome 
Autosomal dominant 
Alport syndrome 
Autosomal recessive 
Alport syndrome 
Benign familial hematuria 
COL4A4 HSA 
2q35-q37 
MMU 1 CFA25 Basement membranes of 
kidney, eye, cochlea, 
lung, brain 
Autosomal dominant 
Alport syndrome 
Autosomal recessive 
Alport syndrome 
Benign familial hematuria 
COL4A5 Xq22.3 X X – 
unlinked 
Basement membranes of 
kidney, eye, cochlea, 
lung, brain, epithelium 
X-linked dominant Alport 
syndome  
Diffuse leiomyomatosis 
(with COL4A6) 
COL4A6 Xq22.3 X X – 
unlinked 
Basement membranes of 
kidney, esophagus, lung, 
epithelium 
Diffuse leiomyomatosis 
(with COL4A5) 
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 Approximately 400 hereditary diseases have been identified in the domestic dog, 
Canis familiaris (Patterson 2001). The diseases affect every modern breed of dog and 
many diseases are clustered within some particularly susceptible breeds. Dissection of 
the genetics responsible for many of the diseases has been hindered, until recently, by 
the lack of a high-resolution map of the canine genome. However, the most recent 
version of the canine map now includes 1800 markers and spans > 90% of the genome 
(Breen et al. 2001).  
 The canine map is comprised of 1,078 microsatellite markers and 372 gene-based 
markers. The microsatellite markers provide the tool for genome scanning of informative 
pedigrees while the gene markers allow examination of syntenic relationships between 
the dog and other mammals. To date, however, fewer than 10 genes have been mapped 
per canine chromosome. In an effort to supplement this, we have undertaken the 
mapping of large gene families that encode structural proteins (Miller et al. 1999, 2001). 
As part of this effort, several members of the collagen gene super-family have been 
cloned and mapped. 
 Reported here is the expansion of the data set of mapped collagen genes. 
Specifically, radiation hybrid mapping of the type I and type IV collagen gene 
subfamilies shows that COL1A1 and COL1A2 are on C. familiaris autosome 9 (CFA9) 
and CFA14, respectively; COL4A1 and COL4A2 map to CFA22; and COL4A3 and 
COL4A4 to CFA25. The COL4A5 and COL4A6 genes likely reside on the X 
chromosome. The work presented here is part of an ongoing study to compare the 
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organization of the collagen gene super-family of the dog and human and to examine the 
roles of type I and IV collagens in hereditary diseases of the dog. 
 
Materials and methods 
Primers for RH mapping  
Partial sequences of canine COL1A1 and COL1A2 (Campbell et al. 1998) and 
COL4A1 to COL4A6 (Thorner et al. 1996) were previously determined. Based on these 
sequences and additional sequencing done during this work (data not shown; see Table 
2), primers were designed to produce PCR products specific for each of these genes. 
PCR was carried out using anonymous canine genomic DNA samples. Resultant 
amplification products were sequenced to verify identity. Primers used and sizes of 
products are listed in Table 2. 
 Amplification of the markers was carried out using standard conditions on dog 
and hamster DNA and also a mixture (1:3) of dog and hamster DNA as previously 
described (Priat et al. 1998). PCR for radiation hybrid (RH) typing were performed 
under different conditions specific for individual markers. For COL1A1, COL1A2 and 
COL4A6, reactions were performed in a final volume of 15 µl using 50 ng RH DNA, 0.3 
µM each primer, 0.316 mM (NH4)2SO4, 67 mM Tris-Cl (pH 8.8 at 25°C), 0.01% Tween-
20, 100 µM each dNTP, 1.5 mM MgCl2, and 0.15 U Biolase Taq (Bioline) using 
annealing temperatures of 59°C, 58°C and 61°C for COL1A1, COL1A2 and COL4A6, 
respectively. For COL4A1 to COL4A5, amplification was performed in 10 µl reactions, 
containing 50 ng RH DNA, 0.3 µM each primer, 250 µM each dNTP (Pharmacia), 2 
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mM MgCl2 (except for COL4A2, 1.5 mM MgCl2), 1X AmpliTaq Buffer and 0.5 U 
AmpliTaq Gold (Perkin-Elmer). PCR reactions were carried out in PTC-200 PCR 
machines (MJ Research). The annealing temperatures for COL4A1 and COL4A2 were 
touchdown programs of 63°C-53°C and 67°C-57°C respectively, consisting of 7 min at 
95°C, 20 cycles of 30 s at 94°C, 30 s at 63°C or 67°C (decreasing 0.5°C per cycle), 1 
min at 72°C and 15 cycles of 30 s at 94°C, 30 s at 53°C or 57°C, 1 min at 72°C, with a 
final extension of 2 min at 72°C. For COL4A3, COL4A4 and COL4A5, classical 
programs with fixed annealing temperatures of 55°C, 63°C and 60°C, respectively, were 
used.  
Mapping analysis  
The eight genes comprising the type I and type IV collagen gene subfamilies 
were integrated into the canine RH map (Breen et al. 2001) using the previously 
described canine-rodent radiation hybrid panel RHDF5000 (Vignaux et al. 1999). Since 
markers are constantly being added to the map, the current version is, of course, replete 
with more markers than the published version. Analysis was done using the two-point 
analysis of the computer program Multimap (Matise et al. 1994a). Markers were 
assigned to linkage groups using a Lod >8.0. Data concerning the canine RH map (Breen 
et al. 2001) are available at: http://www-recomgen.univ-rennes1.fr/doggy.html and 
http://www.fhcrc.org/science/dog_genome/dog.html. 
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Results 
The COL1A1 gene mapped to CFA9, 7.65 centiRay (cR) from GNGT2 and 27.8 
cR from Ren126A15, as previously stated (Breen et al. 2001). Fluorescence in situ 
hybridization (FISH), chromosome paint studies and RH mapping of multiple genes 
suggest that this region of CFA9 corresponds to Homo sapiens autosome 17q (HSA17; 
Werner et al. 1997; Priat et al. 1998; Breen et al. 1999; Yang et al. 1999; Mellersh et al. 
2000), consistent with the observation that human COL1A1 maps to HSA 17q21.3-q22 
(Huerre et al. 1982). Canine COL1A2 mapped to CFA14 with strong Lod scores (>15) 
establishing linkage with the CALCR and PON2 genes (Table 2). This region 
corresponds to regions of HSA7, and human COL1A2 has been mapped to 7q21.3-q22.1 
(Retief et al. 1985).  
The COL4A1 and COL4A2 genes were mapped to CFA22 with high Lod scores 
(Table 2). They are co-localized on the map in a region of conserved synteny with 
human Chr 13, based on RH mapping of F7, ATP4B and GPCR gene marker loci and 
heterologous painting data (Yang et al. 1999; Breen et al. 2001). Their localization 
further confirms the conserved segment of human HSA13 on CFA22. The COL4A3 and 
COL4A4 genes were mapped to CFA25 (Table 2), and are closely linked to one another 
in a region corresponding to a small conserved segment of HSA2q. These data extend 
the coverage of this segment and further define the breakage between HSA2q and 
HSA8p. The COL4A5 and COL4A6 genes remained unlinked in the present version of 
the map. However, these two collagens are linked to each other with a Lod score of 5.3 
(Table 2). They are also linked to microsatellite markers REN130F03 and REN143I17, 
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respectively, with Lod scores of 4.9 for both markers (Table 2). While these Lod score 
values are under the threshold of 8, they are the best Lod scores obtained for COL4A5 
and COL4A6 with any other marker of the map.  Since REN130F03 and REN143I17 are 
localized on the X chromosome, these data strongly suggest that COL4A5 and COL4A6 
reside on the canine X chromosome.  
 
Table 2.  Radiation hybrid mapping of collagen markers on the canine integrated 1800-
marker map.  
Gene  
 
 
Primers (5'–3') Length 
of PCR 
product 
(bp) 
PCR 
Tm 
(oC) 
Canine 
Chr 
(CFA) 
Best Lod 
score with the 
closest 
markers (two-
point analysis 
of MultiMap) 
Accession 
number 
COL1A1 F- ACCTGCCTTCTTGCTT 
     ACACTTC 
R- AGGGCACAGGTGATA 
     CAGTGATA 
800 59 CFA 9 23.7  
GNGT2 
20.5 
REN124K12 
AF291995 
COL1A2 F- TTGACACCCAGACAC 
     ACCAGAGGGGTCTGA 
     TGACACTCTTT 
R- TATTTAAAGCTCACTC 
     AGCATT GCACAGGGT 
     CTCTCGACCT 
2200 58 CFA 14 15.9 
CALCR 
15.8 
PON2  
AF291996 
COL4A1 F- CGGGAGGCGAAGTTA 
     CAC 
R- TAGGCACAGTCAAAC 
     AACAGA 
 
1100 
63-
53 
CFA 22 26.1 
REN183N15 
22.9 
FH2538 
U50933 
COL4A2 F- GGCTGTCCACCACTGC 
     CCCGCT 
R- TATCCAATCCAGAGAC 
     TCCGCCATCCA 
172 67-
57 
CFA 22 26.1 
REN183N15 
22.9 
FH2538 
U50934 
COL4A3 F- TGCCATTCTTGTTCTGT 
     AAC 
R- ATGGCTATGGCAATCG 
     TAGG 
600 55 CFA 25 14.6 
C25.213 
14.4 
REN61G15 
U50935 
COL4A4 F- CACCCTGCCCTTTGCC 
     TACT 
R- GGACACGGCGGGATG 
     GAC 
213 63 CFA 25 11.7 
COL4A3 
9.9 
REN61G15 
U50936 
COL4A5 F- CCCTGGACCAGATGGA 
     ATGC 
R- ACCGTGAGCTCTTTTA 
     TTTCCTTGG 
181 60 unlinked 4.9 
REN130F03 
4.8 
REN307M14 
U07888 
COL4A6 F- GTGAAGCACAGCCAGT 
     CAGAACAG 
R- CTCGCACACCGAACA 
     ACG 
1100 61 unlinked 5.3 
COL4A5 
4.9 
REN143I17 
U50937 
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Discussion 
Placement of gene families or subfamilies on the canine genome map is a 
mechanism not only for rapidly increasing the density of the map, but, more importantly, 
for further establishing the evolutionary relationship between the canine, murine, and 
human genomes. The arrangement of gene families reveals regions of conservation as 
well as evolutionary breakpoints among these genomes. Of particular importance to 
examination of the dog is that mapping of gene families helps to increase the density of 
genes in discrete regions of the canine genome. Finally, sequence and mapping data of 
canine collagen genes facilitate examination of these genes as candidates in study of 
collagen-related hereditary diseases. 
It was found that COL1A1 and COL1A2 mapped to CFA9 and 14, respectively. 
The regions harboring the canine genes exhibit regions of conserved synteny with 
HSA17 and 7, respectively, and, as expected, those are the chromosomes on which the 
human orthologs are found (Table 1). Mapping of COL4A1 and COL4A2 genes to 
CFA22 confirms the region of conserved synteny between CFA22 and HSA13q. The 
COL4A1 and COL4A2 genes are co-localized on the canine genome, i.e., they map to the 
same position on the RH map. This arrangement is also observed in human 
(www.ensembl.org) and mouse (www.ncbi.nlm.nih/LocusLink). In the human, these 
genes are located on HSA13q34 and are separated by only 50 kb. In the mouse, they are 
located at the same locus, which is 85 cM from the telomere on chromosome 8.  
The COL4A3 and COL4A4 genes are closely linked on CFA25. This finding is 
consistent with the breakage between HSA2q and HSA8p previously detected (Yang et 
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al. 1999). The two genes are also organized in tandem in the human and are closely 
positioned on the human draft sequence (www.ensembl.org). This motif is also found in 
the mouse (www.ncbi.nlm.nih/LocusLink).  
The RH data strongly suggest that COL4A5 and COL4A6 genes are linked to 
each other with a Lod of 4.9 by microsatellite markers REN130F03 and REN143I17, 
respectively. Since these two makers are on the X chromosome, it is highly likely that 
COL4A5 and COL4A6 are also on the X chromosome. The X chromosome is the largest 
canine chromosome but is less represented in the RH panel because of haploidy. 
Therefore, the X chromosome is poorly covered (as compared to other chromosomes) in 
the recent version of the map (Breen et al. 2001). This explains why several groups are 
not yet linked together and consequently why COL4A5 and COL4A6 are still unlinked. 
However, these genes have been mapped to the X chromosome in both the human and 
mouse and, due to the highly conserved status of chromosome X throughout mammalian 
evolution, the localization of these two collagens on canine chromosome X is strongly 
favored. With respect to linkage of COL4A5 and COL4A6, in the human these two genes 
are also very close to one another on Xq22.3. This is additional evidence supporting the 
assignment of canine COL4A5 and COL4A6 to the X chromosome.  Finally, the genomic 
organization of type IV collagen genes is similar with respect to their genomic 
exon/intron number, size and organization (Heidet et al. 2001). This feature, associated 
with their tandem organization at several positions on canine, human and murine 
genomes, strongly supports a common ancestral origin and their probable evolution 
through cis and trans duplications. 
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 The canine map currently contains an average of less than ten gene loci per 
chromosome. The addition of more genes belonging to large gene families will further 
improve comparative mapping studies by allowing detection of microrearrangements 
between individual genes. Moreover, the mapping of such gene families also constitutes 
a powerful source of candidate genes for further analyses of diseases of interest. Indeed, 
the current map has more than 500 highly informative microsatellites and may be 
confidently used as a tool for selecting candidate disease regions by linkage analysis. 
Therefore, the detailed mapping and analyses of the collagen type I and IV subfamilies 
presented in this work will help in identifying responsible genes in canine pedigrees in 
which collagen-associated diseases segregate. 
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CHAPTER III 
SEQUENCING AND RADIATION HYBRID MAPPING OF CANINE 
UROMODULIN* 
 
Overview 
Our interest is in understanding the genetic bases for hereditary renal diseases of 
the domestic dog (Canis familiaris) and in characterizing gene loci for placement on the 
map of the canine genome. We report here on the cloning, sequencing and radiation 
hybrid mapping of the canine cDNA encoding Uromodulin (Umod), a renal-specific 
glycoprotein. The cDNA is 2.3 kb in length and, as expected, comparisons of nucleotide 
sequences reveal that canine umod is quite similar to umod of other mammals. The 
predicted amino acid sequence of canine uromodulin has at least 70% identity with other 
mammalian uromodulin proteins. Canine umod has been mapped on the RHDF5000 
radiation hybrid panel and positioned on the most recent canine genome map. Data 
indicate that umod is linked to the marker CZP2 (canine zona pellucida gene) on an RH 
group not yet assigned to a canine chromosome. The human umod and CZP2 genes are 
located on chromosome 16p13.  
 
 
 
 
 
_________________ 
*Reprinted with permission from: Sequencing and radiation hybrid mapping of canine Uromodulin.  Cox 
ML, Quignon P, Galibert F, Lees GE, Murphy KE. (2003a) DNA Seq 14(1), 61-69 
Copyright Taylor & Francis Group: http://www.tandf.co.uk 
 26
Introduction 
Uromodulin (Umod), also known as Tamm-Horsfall glycoprotein (THP), is the 
most abundant protein found in normal mammalian urine. First described by Morner in 
1895 as uromucoid, and characterized by Tamm and Horsfall in 1950 (Kokot and 
Dulawa 2000), gene cloning (Pennica et al. 1987) confirmed that the nucleotide 
sequences of uromodulin and THP are identical. Uromodulin is a cell membrane protein 
with a glycosyl phosphatidylinositol (GPI) anchor (Rindler et al. 1990) and its 
expression is limited to the kidney. Tubular cells in the ascending loop of Henle and 
distal convoluted tubule have Umod on the basal and luminal poles of their cell 
membranes as well as on the membranes of the Golgi body and endoplasmic reticulum 
(Kokot and Dulawa 2000). Depending upon the species, the 85 kDa glycoprotein is 
composed of between 640 and 644 amino acids. The gene is 25 kb and consists of 11 
exons, the first of which is non-coding (Yu et al. 1994; Prasadan et al. 1995), resulting in 
a cDNA of 2.3 kb.  
While a definitive function for Umod has not been established, it has been 
suggested that this glycoprotein may be involved in (1) renal stone and tubulointerstitial 
diseases, (2) host defense mechanisms and (3) function(s) of cytokines and neutrophils. 
Renal stone and tubulointerstitial diseases are common in the human and dog and thus 
are well studied. A role for Umod in these diseases has been postulated due to the fact 
that this protein is found in all cast nephropathies and binds to immunoglobulin light 
chains (Ying and Sanders 2001). Because Umod binds (with high affinity) the type I pili 
of Escherichia coli (Dulawa et al. 1988; Parkkinen et al. 1988), it is possible that the 
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protein has some role in protection against bacterial pathogens. Finally, Umod may play 
a role in host immune responses. This is based on the facts that cytokines IL-1, TNF and 
IL-2 all bind to carbohydrate chains found on the glycoprotein (Sherblom et al. 1988), 
Umod binds to neutrophils (Cavallone et al. 1999) and to T-cells (Mishra et al. 1994) 
and that Umod isolated from the urine of pregnant women is more immunosuppressive 
than that isolated from non-pregnant women (Muchmore et al. 1985). This latter finding 
is correlated with a reduction in the number of oligomannose chains present on Umod of 
pregnant women (Kokot and Dulawa 2000). 
We are interested in hereditary diseases of the dog, and one of our current foci is 
the type IV collagen genes. Three of the type IV collagens, COL4A3, COL4A4 and 
COL4A5 encode proteins important in structure of glomerular basement membranes 
(Kashtan 1998). The COL4A5 gene is especially interesting to us because mutations in it 
cause X-linked Alport syndrome (XLAS) (Kashtan 1998), a disease that occurs in the 
dog and human (Kashtan 1998). During the amplification of the cDNA encoding 
COL4A5, a fragment of the cDNA encoding Umod was fortuitously amplified through 
RT-PCR and RACE. Using gene-specific primers for amplification, umod was 
sequenced in its entirety and RH mapped on the latest canine RH map (Breen et al. 
2001). 
 
Report 
 
Canine renal samples from dogs affected with XLAS were snap-frozen in liquid 
nitrogen at necropsy. Total RNAs were isolated using the SNAP Total RNA Isolation 
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Kit (Invitrogen, Carlsbad, CA). To amplify the full-length cDNA of COL4A5, gene 
specific RT-PCR primers were designed and used to generate overlapping fragments. 
One set of primers, COL4A5-C-F: 5'GTTCTATGGGAGATACTGGTTTGCCTGGATT 
AC3' and COL4A5-C-R: 5'AGGGAGTCCGTTGCGTCCTGGAT3', was used to amplify 
a 950 bp segment at the 3' end of COL4A5.  A 50 µl volume reaction included 50-100 ng 
total RNA and the components of the Advantage One-Step RT-PCR Kit (Clontech BD 
Bioscience, Palo Alto, CA). Conditions for reverse transcription and amplification were 
as follows: 50°C for 60 min and denaturation at 94°C for 5 min, followed by 35 cycles at 
94°C for 30 s, 63°C for 30 s, and 68°C for 1 min, finishing with an extension at 68°C for 
2 min, on a PE 2400 thermal cycler (Perkin-Elmer, Boston, MA). Products were 
resolved by electrophoresis through 1.2% agarose and visualized after staining with 
ethidium bromide.  
Upon electrophoresis, one large amplicon band was visualized. After purification 
using the QIAquik Gel Extraction Kit (Qiagen, Valencia, CA) and re-electrophoresis, 
two PCR products, one of 950 bp and one of 1050 bp, were resolved. Both products 
were inserted into pCR4.0-TOPO (Invitrogen, Carlsbad, CA) and the resultant constructs 
were used to transform chemically competent Escherichia coli TOP10 cells (Invitrogen, 
Carlsbad, CA). After transformation, bacterial colonies were randomly picked, and 
grown overnight in Luria Broth containing 50 ug/ml ampicillin. Plasmids were purified 
using the Plasmid Mini Kit (Qiagen, Valencia, CA) or the PerfectPrep Plasmid Mini Kit 
(Eppendorf, Westbury, NY). Sequencing reactions were carried out using the dye 
termination method and resolved on the 373XL and 377XL automated sequencing 
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machines (Applied Biosystems, Foster City, CA). As expected, the 950 bp fragment was 
derived from COL4A5. Sequence analysis revealed the 1050 bp fragment as a partial 
cDNA derived from umod that corresponds to exons three through seven of human 
umod. This gene is expressed only in the kidney. 
It is interesting that the set of primers amplified two different cDNAs because 
when COL4A5 primers were designed and examined using the BLAST internet tool 
(www.ncbi.nlm.nih.gov/blast/BLAST.cgi), only COL4A5 sequences from various 
organisms were cited as sharing sequence similarity/identity. That is, umod sequences 
from human, cow, mouse and rat were not listed and thus, it was assumed that the 
chosen primers were highly specific. This suggested that the umod product did not arise 
from simple RT-PCR. 
All mRNAs present in the total RNA isolated from canine kidney should have 
been reverse transcribed, using either the oligo(dT) or gene-specific primer as starting 
sites. In the amplification process, cDNAs for both COL4A5 and umod were amplified; 
however, at some point during the cycling, the umod cDNA served as a template for a 3' 
RACE reaction, driven by the anti-sense primer (COL4A5-C-R: 5'AGGGAGTCCGTTG 
CGTCCTGGAT3') for COL4A5 even though this primer and umod are identical at only 
12 of the 23 bases. However, the conditions for amplification allowed the primer to drive 
synthesis of the umod cDNA. This amplification did not include the entire 3' portion of 
the umod cDNA. Since the elongation time during cycling was only one minute, as was 
appropriate for the expected 950 bp fragment of COL4A5, it is likely that this reduced 
time of elongation resulted in the truncated umod cDNA. Regardless, because of the 
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fortuitous amplification, sequencing of the 1050 bp fragment was done so that umod-
specific RACE primers (Table 3) for capture of the 5' and 3' ends of the cDNA and 
subsequent sequencing of it could be designed. Both strands of the entire cDNA were 
sequenced. Assembly of contiguous fragments and determination of the putative amino 
acid sequence for Umod was accomplished using Vector NTI Suite II software 
(Informax, Bethesda, MD).  
 
    Table 3. Primer sets and conditions for the amplification of canine Umod cDNA. 
Primer 
Name 
Type of 
amplification 
Fragment 
size (bp) 
Annealing 
temp (˚C) 
Sequence 
COL4A5-C-R 5' RACE 1050 63 AGGGAGTCCGTTGCGTCCTGGAT 
UMOD-
RACE-2 
5' RACE 740  68 TAACCTGCCCCGTACTCGGTGCTGC 
UMOD-
RACE-3 
3' RACE 830  66 CGGATGGCACTCTTCCAGACTCCTG
ACTAC 
UMOD-F1 RT-PCR 740  Touchdown  
64-60 
F: CTTTCCTCTCTGACCTCGGTGTGG 
R: TGTGCGGTTCACGATGCCCT 
UMOD-F2 RT-PCR 1020 Touchdown  
64-60 
F: CCGTTGCGTCCTGGATGAGTA 
R: AAGGGGTCTGTGGCGTTGCT  
UMOD-F3 RT-PCR 590  Touchdown 
64-60 
F: TAAACATCAGCGTGGGCGGGA 
R: GAAACATCAGGGTCAGGGTGGC 
Urom-Ex8&9 PCR for RH 
mapping 
650 Touchdown 
61-51 
F: ACTGTGAAGTGTATCTCTGCGAC 
R: GGTTTTGGTCTATGATGCCTC 
 
The nucleotide sequence (Figure 1) of canine umod cDNA has been reported to 
GenBank (Accession no. AF498324). The full-length cDNA is 2.3 kb; from the “ATG” 
start codon to the “TGA” stop codon the length is 1929 bp. Comparisons of genomic 
sequences of umod from other organisms to the canine umod cDNA suggest that, as in 
all species reported thus far, the canine gene consists of eleven exons and 10 introns; the 
first exon is non-coding. The exons range in size from 25 bp (exon 1) to 742 bp (exon 3). 
As shown in Figure 1, canine umod is most closely related to human and bovine umod 
with 80.7 and 79.9% identity to bovine and human umod, respectively, using the 
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GeneStream alignment program (http://vega.igh.cnrs.fr/bin/align-guess.cgi) to determine 
percentage identities.  
 
 
dog             GAATTCTACTTTTCTGGCTTCAGGACTCCAGGCATCACAGACAGGGAGGAAACGCCAAGG 60 
cow             --------CCTTTCTGGTTTCAGGACTTCAGGGATCAGGGACAGA-AGGAAATCTCAAGA 51 
human           --------------------CAGGACACCAGACATCAGAGACAGAGAGAAAAATTCAAAG 40 
mouse           ------------------------------------------------------------ 
rat             ------------------------------------------------------------ 
                                                                             
 
dog             GGTCAACCTGTCCTTGCCTTTGGGCAGGTCTTCTCCAGACCAGAAGTAACTGTGAAGAGC 120 
cow             GGCCAGCCTTTCCTTGCCTTTGGGAAAGTCTTC-CCAGACCAGAAGAAGCTGTGAGGAGC 110 
human           GGCCAACCCGTCTTT-CCTTTGGGCAGGTGCTATCTAGACCTGAAGTAGCGG-GAAGAGC 98 
mouse           ------------------------------CCACGCGTCCGCCAGGACAGAGGGCAGAGT 30 
rat             -------------------------------------------GGAATTCCGGGCAGAGC 17 
                                                                   * *  ***  
 
dog             AGAAAAAAATGGGGCAGCTTTCCTCTCTGACCTCGGTGTGGATGGTAGTGGTGGTAACCT 180 
cow             AGAAAGGA-TGAAGTGTCTTTTCTCTCCGAACTTCATGTGGATGGCAGCGGTGGTGACCT 169 
human           AGAAAGGA-TGGGGCAGC---CATCTCTGACTTGGATGCTGATGGTGGTGGTGG---CCT 151 
mouse           GTAAAGGA-TGGGGA------TCCCTTTGACCTGGATGCTGCTGGTAATGATGGTAACCT 83 
rat             ACAAAGGA-TGGGGCAGCTGCTCTCTTTGACCTGGCTGCTGCTGGTTATGGTGGTAACTC 76 
                  ***  * **  *          **  **  *   **  * ***    * ***   *   
 
dog             CTTGGGTCATCATAGCTGCAAACATTGATACTGTGGAAGCAAGAAGCTGCTCTGAATGTC 240 
cow             CTTGGGTCATCATACCTGCAGCAACTGACACCTCATCAGCAAAAAGCTGCTCTGAATGTC 229 
human           CTTGGTTCATCACAACTGCAGCCACTGACACCTCAGAAGCAAGATGGTGCTCTGAATGTC 211 
mouse           CCTGGTTCACTCTGGCTGAAGCCAGTAACTCAACAGAAGCGAGACGGTGTTCTGAATGCC 143 
rat             CCTGGTTCACTGTAGCTGGAGCCAATGACTCACCAGAAGCAAGAAGGTGTTCTGAATGCC 136 
                * *** ***      *** *   * * *  *      *** * * * ** ******** * 
 
dog             ACAGCAATGCCACCTGCATGGAGGATGGGATGGTCACAACATGTTCCTGCCTGGTGGGTT 300 
cow             ACAGCAATGCCACTTGTACGGTGGACGGGGCTGCCACGACCTGCGCCTGCCAGGAGGGCT 289 
human           ACAGCAATGCCACCTGCACGGAGGATGAGGCCGTTACGACGTGCACCTGTCAGGAGGGCT 271 
mouse           ACAACAACGCCACCTGCACGGTGGATGGTGTGGTCACAACGTGCTCCTGCCAGACCGGCT 203 
rat             ACGACAATGCCACCTGTGTGTTGGATGGGGTGGTCACCACATGCTCCTGCCAGGCAGGCT 196 
                **  *** ***** **   *  *** *     *  ** ** **  **** * *   ** * 
 
dog             TCACTGGCAGCGGCTTTGAGTGCGTGGACCTGGATGAATGTGCCATTCCTGGTGCCCACA 360 
cow             TCACTGGCGACGGCCTCGAGTGTGTGGATCTGGACGAATGCGCCGTTCTGGGGGCGCACA 349 
human           TCACCGGCGATGGCCTGACCTGCGTGGACCTGGATGAGTGCGCCATTCCTGGAGCTCACA 331 
mouse           TCACTGGTGATGGGCTGGTGTGTGAGGACATGGATGAGTGTGCTACCCCATGGACTCACA 263 
rat             TCACTGGAGATGGGCTGGTGTGTGAGGACATAGATGAGTGTGCCACCCCGTGGACTCACA 256 
                **** **    **  *    ** * ***  * ** ** ** **    *   *  * **** 
 
dog             ACTGCTCGGAGGGGAGCAGCTGTATGAATACGCTGGGCTCCTACCTCTGCACCTGCCCCG 420 
cow             ACTGCTCCGCCACCAAGAGCTGCGTGAATACGCTGGGCTCTTACACGTGCGTCTGCCCTG 409 
human           ACTGCTCCGCCAACAGCAGCTGCGTAAACACGCCAGGCTCCTTCTCCTGCGTCTGCCCCG 391 
mouse           ACTGCTCC---AACAGCAGCTGTGTGAACACCCCGGGCTCGTTTAAGTGCTCCTGTCAGG 320 
rat             ACTGCTCC---AACAGCATCTGCATGAACACACTGGGCTCCTACGAGTGCTCCTGTCAGG 313 
                *******       *  * ***  * ** ** *  ***** *     ***  *** *  * 
 
 
 
Figure 1. CLUSTAL W (1.82) multiple sequence alignment (http://www.ebi.ac.uk 
/clustalw/).Comparison of nucleotide similarity of canine umod to human (Homo sapiens, 
GenBank Accession no. NM_003361, 79.7%), cow (Bos taurus, GenBank Accession no. 
S75958, 80.7%), mouse (Mus musculus, GenBank Accession no. L33406, 72.6%), and rat 
(Rattus norvegicus, GenBank Accession no. M63510, 80.7%). Percentage identities were 
determined with the GeneStream align program (http://vega.igh.cnrs.fr/bin/align-guess.cgi). 
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dog             ACGGCTTCCGTCTGACACCGGGGCTGGGCTGCATCGACGTGGATGAGTGCTCGGAGCCGG 480 
cow             AAGGTTTTCTCCTGAGCTCGGAGCTCGGCTGCGAGGATGTGGACGAGTGTGCAGAGCCAG 469 
human           AAGGCTTCCGCCTGTCGCCCGGTCTCGGCTGCACAGACGTGGATGAGTGCGCTGAGCCTG 451 
mouse           ATGGTTTTCGTCTGACGCCTGAGCTGAGCTGCACTGATGTGGATGAGTGCTCAGAGCAGG 380 
rat             ATGGCTTTCGTCTGACGCCTGGGCTGGGCTGCATTGATGTGAATGAGTGCACAGAGCAGG 373 
                * ** ** *  ***    * *  **  *****   ** *** * *****  * ****  * 
 
 
dog             GGCTCAGCCGCTGCCATGCCCTGGCCACCTGCATCAACAACAAGGGCAATTACTCGTGCG 540 
cow             GGCTCAGCCGCTGCCACGCCCTGGCCACTTGCATCAATGGCGAGGGCAACTACTCGTGCG 529 
human           GGCTTAGCCACTGCCACGCCCTGGCCACATGTGTCAATGTGGTGGGCAGCTACTTGTGCG 511 
mouse           GGCTCAGTAACTGTCATGCCCTGGCCACCTGTGTCAACACAGAAGGCGACTACTTGTGCG 440 
rat             GGCTCAGTAACTGTCATTCCCTGGCTACCTGTGTCAACACGGAAGGCAGCTACTCATGCG 433 
                **** **   *** **  ******* ** **  ****       ***   ****  **** 
 
dog             TGTGCCCAGCGGGCTACCGAGGGGACGGGCAGCACTGTGAGTGCTCCCCGGGCTCCTGCG 600 
cow             TGTGTCCTGCGGGCTACCTGGGAGACGGAAGGCACTGTGAGTGTTCCCCGGGCTCCTGTG 589 
human           TATGCCCCGCGGGCTACCGGGGGGATGGATGGCACTGTGAGTGCTCCCCGGGCTCCTGCG 571 
mouse           TGTGTCCCGAGGGCTTTACAGGGGATGGTTGGTACTGTGAGTGCTCCCCAGGCTCCTGTG 500 
rat             TGTGTCCCAAGGGCTATAGAGGGGATGGTTGGTACTGTGAGTGCTCCCCTGGCTTCTGTG 493 
                * ** **   *****     ** ** **   * ********** ***** **** *** * 
 
dog             GCCCGGGCTTGGACTGCGTGCCCGTGGGC------GACGCGCTGGTGTGCGCGGACCCGT 654 
cow             GGCCTGGGCTAGACTGCGTGCGGGAGGGC------GACGCGCTCGTGTGCGTGGACCCGT 643 
human           GGCCGGGGTTGGACTGCGTGCCCGAGGGC------GACGCGCTCGTGTGCGCGGATCCGT 625 
mouse           AGCCAGGACTGGACTGCTTGCCCCAGGGCCCGGATGGAAAGCTGGTGTGTCAAGACCCCT 560 
rat             AGCCAGGGCTGGACTGCTTGCCTCAGGGTCCCAGTGGAAAGCTGGTGTGCCAAGACCCCT 553 
                  ** **  * ****** ***    ***       *    *** *****    ** ** * 
 
dog             GCCAGGAGCATCGCATCCTGGATGAGTACTGGCGCAGCACCGAGTACGGGGCAGGTTACA 714 
cow             GCCAGGTGCACCGCATCCTGGACGAATACTGGCGCAGCACAGAGTACGGCTCCGGCTACA 703 
human           GTCAGGCGCACCGCACCCTGGACGAGTACTGGCGCAGCACCGAGTACGGGGAGGGCTACG 685 
mouse           GCAATACATATGAGACCCTGACTGAGTACTGGCGCAGCACAGAGTATGGTGTGGGCTACT 620 
rat             GCAATGTCTATGAAACCCTGACTGAGTACTGGCGCAGCACAGACTATGGTGCCGGCTACT 613 
                *  *     *    * ****   ** ************** ** ** **    ** ***  
 
dog             CCTGCGACGTGGGCCTGAACGGCTGGTACCGCTTCACAGGGCCAGGTGGGGTGCGCCTGG 774 
cow             TCTGTGATGTCAGTCTGGGCGGCTGGTACCGCTTCGTGGGCCAGGCCGGCGTGCGCCTGC 763 
human           CCTGCGACACGGACCTGCGCGGCTGGTACCGCTTCGTGGGCCAGGGCGGTGCGCGCATGG 745 
mouse           CCTGTGACGCGGGTCTGCACGGCTGGTACCGGTTCACAGGCCAGGGTGGCGTTCGCATGG 680 
rat             CCTGTGACTCAGATATGCACGGCTGGTACCGGTTCACAGGCCAGGGTGGCGTTCGCATGG 673 
                 *** **        **  ************ ***   ** *  *  ** *  *** **  
 
dog             CGGAGACCTGCGTGCCAGTCCTGCACTGCAACACGGCCGCGCCCATGTGGCTCAATGGCA 834 
cow             CCGAGACCTGCGTGCCCGTCCTGCACTGCAACACGGCCGCGCCTATGTGGCTCAACGGCA 823 
human           CCGAGACCTGCGTGCCAGTCCTGCGCTGCAACACGGCCGCCCCCATGTGGCTCAATGGCA 805 
mouse           CTGAGACCTGTGTGCCCGTCCTGCGATGCAACACGGCGGCACCCATGTGGCTCAATGGCT 740 
rat             CTGAGACCTGTGTGCCCGTACTGAGGTGCAACACGGCTGCACCCATGTGGCTCAATGGCT 733 
                * ******** ***** ** ***   *********** ** ** *********** ***  
 
dog             CACACCCGACCAGAGACCAGGGCATCGTGAACCGCACAGCCTGTGCGCACTGGAGGGGCC 894 
cow             CGCATCCATCGAGCGACGAGGGCATCGTGAACCGCGTGGCCTGTGCACACTGGAGCGGTG 883 
human           CGCATCCGTCCAGCGACGAGGGCATCGTGAGCCGCAAGGCCTGCGCGCACTGGAGCGGCC 865 
mouse           CTCATCCCTCGAGTAGTGAAGGCATTGTGAGCCGCACGGCCTGTGCACACTGGAGCGACC 800 
rat             CGCATCCTTCGAGCAGAGAGGGCATTGTGAGCCGCACAGCCTGCGCACACTGGAGCGACC 793 
                * ** **  * **     * ***** **** ****   ***** ** ******** *    
 
dog             ACTGCTGCCTGTGGGATGCGTCCATCCAGGTGAAGGCCTGCGCCGGCGGCTACTATGTCT 954 
cow             ACTGCTGCCTGTGGGACGCGCCCATCCAAGTGAAGGCCTGTGCCGGGGGCTACTACGTGT 943 
human           ACTGCTGCCTGTGGGATGCGTCCGTCCAGGTGAAGGCCTGTGCCGGCGGCTACTACGTCT 925 
mouse           AATGCTGCCGGTGGTCCACAGAGATCCAGGTGAAGGCTTGCCCAGGTGGCTTCTATATTT 860 
rat             ACTGCTGCCTGTGGTCCACAGAGATCCAGGTGAAGGCCTGCCCTGGTGGCTTCTATGTTT 853 
                * ******* ****    *     **** ******** **  * ** **** ***  * * 
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dog             ACAACCTCACGGAGACCCCTGAGTGCTACCTGGCCTACTGCACAGACCCCACCTCTGTGT 1014 
cow             ACAACCTGACGGCGCCCCCTGAGTGCCATCTGGCTTACTGCACAGACCCCAGCTCTGTGG 1003 
human           ACAACCTGACAGCGCCCCCCGAGTGTCACCTGGCGTACTGCACAGACCCCAGCTCCGTGG 985 
mouse           ACAACTTGACAGCGCCCCCTGAGTGCAATCTGGCTTACTGCACCGATCCTAGTTCCGTGG 920 
rat             ACAACTTGACAGAGCCCCCTGAGTGCAATCTGGCTTACTGCACCGATCCTAGCTCCGTGG 913 
                ***** * ** * * **** *****  * ***** ******** ** ** *  ** ***  
 
dog             TGGGGACATGTGAGGAGTGCAGTGTAGAAGAGGACTGCAAATCCCATGATGGCATGTGGA 1074 
cow             AGGGGACGTGTGAGGAGTGCCGTGTGGATGAGGACTGCAAATCGGATAATGGTGAATGGC 1063 
human           AGGGGACGTGTGAGGAGTGCAGTATAGACGAGGACTGCAAATCGAATAATGGCAGATGGC 1045 
mouse           AGGGGACTTGCGAAGAATGCAGGGTAGATGAAGATTGCATATCGGATAACGGCAGATGGC 980 
rat             AGGGGACTTGCGAAGAATGCGGGGTAGATGAAGACTGCGTATCTGATAACGGCAGATGGC 973 
                 ****** ** ** ** *** *  * ** ** ** ***  ***  ** * **    ***  
 
dog             GCTGCCAGTGCAAACAGGACTTCAATGTCACTGATCTCTTCCTTCTGGACCG---GCTGG 1131 
cow             ACTGCCAGTGCAAACAGGACTTCAACGTCACCGATCTCTCCCTCCTGGAGCGCAGGCTGG 1123 
human           ACTGCCAGTGCAAACAGGACTTCAACATCACTGATATCTCCCTCCTGGAGCACAGGCTGG 1105 
mouse           GCTGCCAGTGTAAACAGGACTCCAACATCACAGATGTCTCCCAATTGGAGTACAGGCTGG 1040 
rat             GCTGCCAGTGTAAACAGGACTTCAACGTTACAGATGTCTCCCTCCTGGAGCACAGGCTGG 1033 
                 ********* ********** ***  * ** *** *** **   ****      ***** 
 
dog             AGTGTAGGCCCAATGATATCAAGGTGTCCCTGAGCAAGTGTCAGCTGAAGAGCCTGGGCT 1191 
cow             AATGTGGGGTTGATGACATTAAGTTGTCCCTGAGCAAGTGCCAGCTGAAGAGTCTGGGCT 1183 
human           AATGTGGGGCCAATGACATGAAGGTGTCGCTGGGCAAGTGCCAGCTGAAGAGTCTGGGCT 1165 
mouse           AGTGTGGGGCCAATGACATCAAGATGTCCCTCAGAAAGTGCCAGCTACAGAGTTTGGGCT 1100 
rat             AGTGTGAGGCCAATGAAATCAAGATATCCCTCAGCAAGTGCCAGCTACAGAGTTTGGGCT 1093 
                * ***  *    **** ** *** * ** **  * ***** *****  ****  ****** 
 
dog             TTGAGAAGGTTTTCATGTACCTGCGTGACAGCCAGTGCTCAGGCTTCAATGAGAGGGGCG 1251 
cow             TTGAGAAGGTCTTCATGTACCTGCATGACAGCCAGTGCTCAGGCTTCACTGAGAGGGGCG 1243 
human           TCGACAAGGTCTTCATGTACCTGAGTGACAGCCGGTGCTCGGGCTTCAATGACAGAGACA 1225 
mouse           TTATGAATGTCTTCATGTACCTGAATGACAGACAATGCTCAGGCTTCAGTGAGAGTGATG 1160 
rat             TTATGAAGGTCTTCATGTACCTGAATGACAGACAGTGCTCAGGCTTCAGTGAGAGGGGTG 1153 
                *    ** ** ************  ****** *  ***** ******* *** ** *    
 
dog             ACCGGGACTGGGTATCTGTGGTGACCCCAGCCAGGGATGGTCCCTGTGGAACAGTGATGG 1311 
cow             ACCGGGACTGGATGTCTGTGGTGACCCCAGCCAGGGATGGCCCCTGTGGGACAGTGATGA 1303 
human           ACCGGGACTGGGTGTCTGTAGTGACCCCAGCCCGGGATGGCCCCTGTGGGACAGTGTTGA 1285 
mouse           AACGAGACTGGATGTCCATAGTGACCCCTGCCAGGAATGGTCCCTGTGGGACAGTATTGA 1220 
rat             AACGAGACTGGATGTCCATAGTGACTCCTGCCAGGGATGGTCCCTGTGGGACAGTATTGA 1213 
                * ** ****** * **  * ***** ** *** ** **** ******** *****  **  
 
dog             TGAGGAATGAAACTCATGCCACATACAGCAACACTCTTTACCTGGCAGATGAGATCGTCA 1371 
cow             CGAGGAATGAGACCCACGCCACATACAGCAACACTCTCTACCTGGCAGATGAGATCATCA 1363 
human           CGAGGAATGAAACCCATGCCACTTACAGCAACACCCTCTACCTGGCAGATGAGATCATCA 1345 
mouse           GGAGAAACGAAACCCATGCCACCTACAGCAACACCCTCTACCTGGCAAATGCGATCATCA 1280 
rat             GGAGAAATGAAACCCACGCCACCTACAGCAACACCCTCTACCTGGCAAGTGAGATCATCA 1273 
                 *** ** ** ** ** ***** *********** ** *********  ** **** *** 
 
dog             TCCGTGACCGCAACATCAAAATCAACTTTGAGTGTTCCTACCCCCTGGATATGAAAGTGA 1431 
cow             TCCGTGACCTCAACATCAGAATCAACTTTGCGTGCTCCTATCCCCTGGACATGAAAGTCA 1423 
human           TCCGTGACCTCAACATCAAAATCAACTTTGCATGCTCCTACCCCCTGGACATGAAAGTCA 1405 
mouse           TTCGGGACATCATCATAAGAATGAACTTTGAATGCTCTTACCCTCTGGACATGAAAGTCA 1340 
rat             TCAGGGATATCAACATCAGAATCAACTTTGAATGCTCTTACCCTCTGGACATGAAAGTCA 1333 
                *  * **   ** *** * *** *******  ** ** ** ** ***** ******** * 
 
dog             GCTTGGAGACCTCCCTGCAGCCGATAGTCAGCTCTCTAAACATCAGCGTGGGCGGGACAG 1491 
cow             GCCTGAAGACCTCCCTGCAGCCAATGGTCAGTGCCCTCAACATCAGCATGGGCGGGACCG 1483 
human           GCCTGAAGACCGCCCTACAGCCAATGGTCAGTGCTCTAAACATCAGAGTGGGCGGGACCG 1465 
mouse           GCCTGAAGACCTCCCTACAGCCCATGGTCAGTGCCCTGAACATCAGCTTGGGTGGGACAG 1400 
rat             GTCTGAAGACCTCCCTACAGCCTATGGTTAGTGCCTTGAACATCAGCTTGGGTGGGACAG 1393 
                *  ** ***** **** ***** ** ** **  *  * ********  **** ***** * 
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dog             GCATGTTCACCGTGCGGATGGCACTCTTCCAGACTCCTGACTACACACAGCCCTACCAAG 1551 
cow             GCACATTCACCGTGCGAATGGCACTCTTCCAGAGCCCTGCCTACACACAGCCCTACCAAG 1543 
human           GCATGTTCACCGTGCGGATGGCGCTCTTCCAGACCCCTTCCTACACGCAGCCCTACCAAG 1525 
mouse           GCAAGTTCACCGTGCGGATGGCATTGTTCCAGAGCCCTACCTACACACAGCCCCACCAAG 1460 
rat             GCAAGTTCACTGTGCAGATGGCACTGTTCCAGAACCCTACCTACACACAGCCCTACCAAG 1453 
                ***  ***** ****  *****  * *******  ***  ****** ****** ****** 
 
dog             GCTCCTCTGTGACCCTGACTATCGAGGCCTTTCTCTATGTGGGCACCATGCTGGATGGGG 1611 
cow             GCTCCTCTGTGACCCTGTCCACAGAAGCGTTTCTCTACGTCGGCACCATGCTGGATGGGG 1603 
human           GCTCCTCCGTGACACTGTCCACTGAGGCTTTTCTCTATGTGGGCACCATGTTGGATGGGG 1585 
mouse           GTCCTTCTGTGATGCTGTCCACTGAGGCTTTTCTGTATGTGGGCACCATGCTGGATGGGG 1520 
rat             GTCCTTCTGTGATGCTCTCCACTGAGGCTTTTCTGTATGTGGGCACCATGCTGGATGGGG 1513 
                *  * ** ****  **  * *  ** ** ***** ** ** ********* ********* 
 
dog             GTGATTTGTCCCGGTTTGCACTGCTGATGACTAACTGTTATGCCACACCCAGCAGCAACG 1671 
cow             GTGACTTGTCCCGGTTTGTACTGCTCATGACCAACTGCTATGCCACACCCAGCAGCAATG 1663 
human           GCGACCTGTCCCGATTTGCACTGCTCATGACCAACTGCTATGCCACACCCAGTAGCAATG 1645 
mouse           GTGACTTGTCCCGGTTTGTACTGCTAATGACCAACTGCTATGCCACACCCAGTAGCAACT 1580 
rat             GTGACTTGTCCCGGTTTGTACTGCTAATGACCAACTGCTATGCCACACCCAGTAGCAACT 1573 
                * **  ******* **** ****** ***** ***** ************** *****   
 
dog             CCACAGACCCCTTGAAGTACTTCATCATCCAGGACAGATGTCCACGCACTACGGACTCAA 1731 
cow             CCACAGACCCCTTGAAATACTTCATCATCCAGGACAGATGTCCACGTGCTGCGGACTCAA 1723 
human           CCACGGACCCCCTGAAGTACTTCATCATCCAGGACAGATGCCCACACACTAGAGACTCAA 1705 
mouse           CCACAGACCCTGTGAAATACTTCATTATCCAGGACAGTTGTCCACGTACAGAAGATACAA 1640 
rat             CCACGGACCCTGTAAAATACTTCATTATCCAGGACAGATGTCCACATACAGAAGATACAA 1633 
                **** *****  * ** ******** *********** ** ****   *    **  *** 
 
dog             CCATCCAGGTGGTGGAGAATGGGGAGTCCCCTCAGGGCCGATTTTCTGTACAGATGTTCC 1791 
cow             CCATCCAAGTGGAGGAGAATGGGGAGTCCCCTCAGGGCCGGTTTTCTGTCCAGATGTTCC 1783 
human           CTATCCAAGTGGTGGAGAATGGGGAGTCCTCCCAGGGCCGATTTTCCGTCCAGATGTTCC 1765 
mouse           CCATTCAGGTGACAGAGAATGGCGAGTCATCTCAGGCCCGATTTTCTGTTCAGATGTTCC 1700 
rat             CCATTCAGGTGACAGAGAATGGCGAGTCCTCTCAGGCCCGGTTCTCTATTCAGATGTTCC 1693 
                * ** ** ***   ******** *****  * **** *** ** **  * ********** 
 
dog             GTTTTGCCGGGAACTACGACCTGGTCTACCTGCACTGTGAAGTGTATCTCTGCGACATCA 1851 
cow             GTTTTGCTGGAAACTACGACCTGGTGTACCTGCATTGTGAAGTGTATCTCTGTGACACCG 1843 
human           GGTTTGCTGGAAACTATGACCTAGTCTACCTGGACTGTGAAGTCTATCTCTGTGACACCA 1825 
mouse           GGTTTGCAGGAAACTACGACCTTGTCTACCTTCACTGCGAGGTGTACCTATGTGACTCTA 1760 
rat             GGTTTGCAGGAAACTCCGACCTTGTCTACCTTCACTGCGAGGTGTACCTGTGTGACACTA 1753 
                * ***** ** ****  ***** ** *****  * ** ** ** ** ** ** ***     
 
dog             TTAATGAAAAATGCAAACCTACCTGCTCTGGGACCAGATTCCGCAGTGGAGGCATCATAG 1911 
cow             TGAATGAAAAGTGCAGACCTACCTGCCCTGAGACCAGATTCCGCAGTGGGAGCATCATAG 1903 
human           TGAATGAAAAGTGCAAGCCTACCTGCTCTGGGACCAGATTCCGAAGTGGGAGTGTCATAG 1885 
mouse           CGAGTGAACAGTGTAAACCTACCTGCTCTGGTACTAGATTTCGAAGTGGGAACTTCATAG 1820 
rat             TGAGTGAGCAGTGTAAACCTACCTGTTCTGGTACTAGATATCGAAGTGGGAACTTCATAG 1813 
                  * ***  * ** *  ********  ***  ** ****  ** *****     ****** 
 
dog             ACCAAAGCCGCGTCCTGAACTTGGGTCCCATCACACGGAAAAATGTCCAGGCAGTGGTCT 1971 
cow             ACCAAACCCGTGTCCTGAACTTGGGTCCCATCACACGGAAGGGGGGCCAGGCTGCAATGT 1963 
human           ATCAATCCCGTGTCCTGAACTTGGGTCCCATCACACGGAAAGGTGTCCAGGCCACAGTCT 1945 
mouse           ATCAGACCCGTGTCCTGAACTTGGGTCCCATAACACGACAAGGTGTCCAGGCCTCAGTGT 1880 
rat             ATCAGACCCGTGTCCTGAACTTGGGTCCCATCACACGACAAGGTGTCCAGGCCTCAGTGT 1873 
                * **   *** ******************** *****  *    * ******     * * 
 
dog             CAAGGGCTGCTTCCAGCAGCTTGGGGTTCCTGAAGGTCTGCCTGCCTCTGCTTCTATCGG 2031 
cow             CAAGGGCTGCTCCCAGTAGCTTGGGGCTTCTGCAGGTCTGGCTGCCTCTGCTTCTGTCGG 2023 
human           CAAGGGCT---TTTAGCAGCTTGGGGCTCCTGAAAGTCTGGCTGCCTCTGCTTCTCTCGG 2002 
mouse           CCAAGGCTGCTTCCAGCAACTTGAGGCTCCTGAGCATCTGGCTGCTGTTGTTTCCCTCAG 1940 
rat             CCAAGGCTGCTTCCAGCAACTTGGGGTTCCTGAGCATCTGGCTGCTGCTGTTTCTCTCAG 1933 
                * * ****      ** * **** ** * ***    **** ****   ** ***  ** * 
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dog             CCACCCTGACCCTGATGTTTCAGTGATTGGCAGCTGGAAACCCTGTGCTCTGTGGCT--- 2088 
cow             CCACTTTGACCCTGATGTCTCCGTGACTG-TGGCCGGAAATCCTGTACTCTGTGGCTACC 2082 
human           CCACCTTGACCCTGACTTTTCAGTGACTGACAGCGGAAAGCCCTGTGCTCCATGGCTGCC 2062 
mouse           CCACTTTGATCTTCATGGTTCAATGATGGAAAGCAGAAAACCTGGT-----GTGGCTCCC 1995 
rat             CTACTTTGACCCTGATGGTTCATTGATGGAAAACAGAAAACCTGGT-----GTGGCTCCC 1988 
                * **  *** * * *    **  ***  *    * * **  *  **      *****    
 
dog             ----TCA-TTCCTGCTGGCTG-GGGAT--GATGCCGCTTAGTGCTCCAGCCACAGAAAAG 2140 
cow             AAACTCACTTTCTACTGACTGCGAGGC--CATGCAGGCTAGCACTCCACCCATAGAGAAA 2140 
human           AT-CTCACCTCCTGCTGGGCAGGGGGCATGATGCGGGCCAGTGCTCCAGCCACAGAAAAG 2121 
mouse           AG-CTCACTTCCTGCTGGCCAGGAGTGGGGATGCAGGCTGGTTATC-AGCCAGGAGAGAG 2053 
rat             AG-TTCACTTCCTGCTGGCCAGGAGTGGGGATGCAGGCTGGTAAGC-AGCCAGGAGAGAG 2046 
                    ***  * ** ***     * *     **** *    *    * * ***      *  
 
dog             GGAACTCACACTTCAGTCAC-CTGCTCCT-CTTTCCCCACCTTTAATCCTCATTATCACA 2198 
cow             GGAGCCCACACTTCAGTCACTCTGCTCCTATTTTTCTCCCCTTTAATCCTTGTTACCAAA 2200 
human           AAAGTTCATGCTTTGTTCAGCCTG--CCTTCTTTTCTCCCTTTTAATCCTGGCTGTCGAG 2179 
mouse           GGAGCTCACACTGCCTCCAGCTTGCACGTACTCTTT----CTTTAATCCTCACCATCA-A 2108 
rat             GGAGCTCACACTGCCTCCAGCTTGCACTTACCCTTTT--CCTTTAACCCTCACCATCA-A 2103 
                  *   **  **     **   **  * *    *       ***** ***      *    
 
dog             AAATATCTTAATATCTTTAAATTCTGCCTTCTTTCAAAATGGGACTTGTGACATGTGTGC 2258 
cow             AAAATAGCCTGTGTCTTTAAATGCTGCTTTCTCTCAAAATGGGTCTTGTGATATGTCTGT 2260 
human           AAACA-GCCTGTGTCTTTAAATGCTGCTTTTTCTCAAAATGGGACTTGTGACG---GTGT 2235 
mouse           AAACAAGTTGGCATCTTTCAGTGCTGTTCTTCCTTCAAATG-------TGATATGT---- 2157 
rat             AACCGAGTTGATATCTTTCAATGCTGCTGATTCTTCAACTGGAACTTGTAATGTGTCTGT 2163 
                **           ***** * * ***       *  ** **       * *          
 
dog             ACATGAGGCCCCATGTCTCCTTAAAGATTGTGGCAAAATAATAAT-----AATTTTAAGA 2313 
cow             TCATGAGGCCCC-TATCTCCTTAAAGGGTATTGCAAAATAATAATTAAAAAAAGCTCAGT 2319 
human           ACCTGAGGCCCC-CATCTCCTTAAAGAGTGTGGCAAAATAATGATTTTTAAATCTC---- 2290 
mouse           --ATGAAGCCCC-TGTCTCCTGAAGGAATGTGGCAAAATAATAAGTTTAAAGTATCAAAA 2214 
rat             ACATGAAGCCCC-TGTCTCTTTAAGGAATGTATCAAAATAATAAGTTTAAAACAATCCGG 2222 
                   *** *****   **** * ** *  * *  ********* *      *          
 
dog             AAAAAAAAAAAAAAAAAAAAAA 2335 
cow             CTAAAAAAAAAAAAAAAAAAA- 2340 
human           ---------------------- 
mouse           AAAAAAAAAAAAAAA------- 2229 
rat             AATTC----------------- 2227 
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The predicted canine Umod contains 642 amino acids and has an estimated 
molecular weight (not including associated carbohydrate moieties) of 72039.96 kDa 
(Peptide Molecular Weight Calculator: http://elmo.ucsc.edu/MWform.html). The 
putative canine Umod has 81.8 and 82.3% similarity at the amino acid level to bovine 
and human Umod, respectively. As expected, nucleotide and amino acid sequences of 
uromodulin of the mouse and rat are slightly more divergent; there is 72.6% identity and 
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72.0% similarity of nucleotide and amino acid sequences between dog and mouse, and 
70.9% identity and 75.2% similarity of nucleotide and amino acid sequences between 
dog and rat. 
Umod has been localized to human HSA16p13.11 (Jeanpierre et al. 1993; Pook 
et al. 1993), murine MMU7F1-F2 (Fukuoka and Matsuda 1997), and rat RNO1q36-q37 
(Fukuoka and Matsuda 1997). In order to add type I loci to the map of the canine 
genome and add data on synteny among species, primers for radiation hybrid mapping of 
canine umod were designed: Umod-Ex8/9: 5'ACTGTGAAGTGTATCTCTGCGAC3' 
and 5'GGTTTTGGTCTATGATGCCTC3'. Amplification using these primers generated 
a PCR product of 650 bp from a stock canine genomic DNA sample. Amplifications 
were performed in 10 µl reactions containing 50 ng DNA of each of the RHDF5000 
hybrid cell lines, 0.3 µM of each primer, 250 µM of each dNTP (Pharmacia, Peapack, 
NJ), 2 mM MgCl2, 1X AmpliTaq Buffer and 0.5 U AmpliTaq Gold (Perkin-Elmer, 
Boston, MA). PCR reactions were carried out in PTC-200 thermal cyclers (MJ Research, 
Waltham, MA) with the following program: 8 min 94°C, followed by 20 cycles of 30 s 
94°C, 30 s 61°C (decreasing of 0.5°C per cycle), 1 min 72°C and 15 cycles of 30 s 94°C, 
30 s 51°C, 1 min 72°C and a final extension of 3 min 72°C. PCR products were 
separated by electrophoresis through 2% agarose and visualized after staining with 
ethidium bromide. Results were scored in terms of present, absent or ambiguous in each 
of 126 hybrid cell lines composing the radiation hybrid panel (Vignaux et al. 1999). 
These data were computed based on the most recent version of the canine map (Breen et 
al. 2001) using the Multimap package (Matise et al. 1994b). In this study, a two-point 
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analysis was performed, i.e., the program computed the umod RH data against the 1500 
RH data of the previous map, and gave the marker which has the best Lod score among 
all of the markers. 
RH mapping revealed that canine umod is linked to the zona pellucida gene, 
CZP2, with a Lod score of 13.8, in a small RH group not yet assigned to a canine 
chromosome. Due to tight linkage with CZP2, the fragments amplified using RH primers 
for CZP2 and umod were sequenced to confirm that they were two separate genes (data 
not shown). The umod and CZP2 genes are also linked in human, and are located on 
chromosome HSA16p13.11 and HSA16p12, respectively. These regions of HSA16 
(16p13.11 and 16p12) have been shown through fluorescence in situ hybridization to 
have conservation of synteny with the central part of canine chromosome 6 (Breen et al. 
2001), suggesting that umod and CZP2 will probably be located in this region of CFA6 
in future RH maps. Interestingly, umod is one of a tentative gene family that includes the 
zona pellucida genes ZP2 and ZP3, the exocrine pancreas zymogen granule membrane 
glycoprotein gene GP2, and the beta-glycan (TGF-β receptor III) gene. 
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CHAPTER IV 
GENETIC CAUSE OF X-LINKED ALPORT SYNDROME IN A FAMILY OF 
DOMESTIC DOGS* 
Overview 
Alport syndrome is a hereditary disease of type IV (basement membrane) 
collagens that occurs spontaneously in humans and dogs. In the human XLAS is caused 
by mutations in COL4A5, resulting in absence of type IV collagen α5 chains from the 
GBM of affected individuals. The consequence of this defect is progressive renal failure 
for which the only available treatments are dialysis and transplantation. Recent studies 
support the prospect of gene transfer therapy for Alport syndrome, but further 
development of required technologies and demonstration of safety and efficacy must be 
accomplished in a suitable animal model. We previously identified and have propagated 
a family of mixed-breed dogs with an inherited nephropathy that exhibits the clinical, 
immunohistochemical, pathological, and ultrastructural features of human XLAS. To 
identify the causative mutation, COL4A5 cDNAs from normal and affected dogs were 
sequenced in their entirety. Sequence analyses revealed a 10 bp deletion in exon 9 of 
affected dogs. This deletion causes a frame-shift that results in a premature stop codon in 
exon 10. Characterization of the causative mutation was followed by development of an 
allele-specific test for identification of dogs in this kindred that are destined to develop 
XLAS.  
_______________ 
*Reprinted with permission from Cox ML, Lees GE, Kashtan, Murphy KE (2003b) Genetic cause of X-
linked Alport syndrome in a family of domestic dogs. Mamm Genome 14, 396-403 
Copyright Springer-Verlag GmbH & Co.KG 
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Introduction 
 
  Alport syndrome is a hereditary progressive renal disease that is often associated 
with hearing loss, ocular abnormalities, or both, and rarely with leiomyomatosis 
(Kashtan 1998; Tryggvason and Martin 2001). The disease is caused by mutations in 
genes that encode certain members of the type IV collagen family of peptides. Type IV 
collagen is an important structural component of BM, the thin, sheet-like extracellular 
matrices that separate cells from their underlying stroma in tissues throughout the body 
(Hudson et al. 1993; Miner 1999). Similar to other collagens, type IV collagen is a 
triple-helical protein consisting of three α chains. The collagen α chains have (Gly-Xaa-
Yaa)n repeats, with glycine being the only amino acid small enough to fit into the center 
of  the triple helix. Type IV collagen α chains have many interruptions in their Gly-Xaa-
Yaa repeats, allowing for flexible kinks in the triple helix. In addition to the collagenous 
domain, type IV collagen α chains have a carboxyterminal noncollagenous (NC1) 
domain and an aminoterminal noncollagenous (7S) domain that are important for their 
assembly into a network structure. Six genetically distinct type IV collagen α chains 
have been described. The α1(IV) and α2(IV) chains are ubiquitous in BM and are 
present in triple-helical molecules in a 2:1 ratio. The other α chains have variable and 
more restricted BM distributions (Miner 1999). 
  Alport syndrome is an uncommon, but nonetheless important cause of human 
ESRD worldwide. One recent estimate, based on data from Finland, was that the birth 
prevalence of AS was about 1 in 53,000 live births (Pajari et al. 1996). Such data likely 
apply to large populations of European origin, but data regarding large populations of 
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other geographic origins are lacking (Levy and Feingold 2000). In Europe, AS accounts 
for 1.5% of children starting renal replacement therapy (Loirat et al. 1994). In the United 
States, AS affects about 3% of children with chronic renal failure and about 0.3% of 
adults with ESRD (United States Renal Data System 1996). 
  Alport nephropathy develops as a consequence of absence from the GBM of a 
crucial assembly of type IV collagen heterotrimers containing α3, α4, and α5 peptide 
chains (Gunwar et al. 1998; Tryggvason and Martin 2001). A defect in any one of the 
three genes (COL4A3, COL4A4, and COL4A5) encoding these chains can disrupt proper 
assembly of the α3/α4/α5 chain network, which is required for maintenance of adult 
GBM structure and function (Harvey et al. 1998). In 80-85% of families, AS is X-linked 
(i.e., XLAS) and caused by mutations in the COL4A5 gene which encodes the α5(IV) 
collagen chain (Barker et al. 1990; Hostikka et al. 1990). Since the first report of a 
causative mutation in COL4A5 (Barker et al. 1990), more than 350 other mutations have 
been identified in XLAS patients (Martin et al. 1998; Inoue et al. 1999; Jais et al. 2000).  
About 15% of AS cases are autosomal recessive, and autosomal dominant inheritance of 
AS occurs rarely (Kashtan 1998). Autosomal forms of AS are caused by mutations in the 
COL4A3 or COL4A4 genes (Lemmink et al. 1994; Mochizuki et al. 1994; Boye et al. 
1998; Heidet et al. 2001; Longo et al. 2002), which are located on human Chromosome 
(Chr) 2. Almost all AS mutations are private; most are point mutations, small deletions 
or insertions (Tryggvason and Martin 2001). Those causing substitutions of a glycine 
residue within the collagenous domain may produce a less severe disease phenotype; 
however, nonsense mutations, splice site mutations, and large rearrangements usually 
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produce more severe phenotypes with earlier onset of disease (Gross et al. 2002). 
Additionally, large deletions involving certain portions of COL4A5 and COL4A6, which 
is adjacent to COL4A5 on the X Chr, result in Alport syndrome and diffuse 
leiomyomatosis (Tryggvason and Martin 2001). 
Although type IV collagen abnormalities have been identified as the inciting 
cause of AS, important aspects of AS remain ill defined (Kashtan 2002). For example, 
the complete absence of the GBM α3/α4/α5 chain network does not impair glomerular 
development nor does it cause glomerular function to be abnormal early in life (Harvey 
et al. 1998). Also, mechanisms linking the type IV collagen defects to subsequent events, 
beginning with GBM changes and culminating with ESRD, are incompletely understood 
(Kashtan 2002). Moreover, treatments of proven efficacy to retard or halt progression of 
renal failure in AS patients are not available. Thus, dialysis and eventual renal 
transplantation currently are the mainstays of treatment for patients with AS (Kashtan 
1998; Tryggvason and Martin 2001).  
Availability of suitable animal models provides needed opportunities for 
investigation of the pathogenesis and treatment of AS (Kashtan 2002). Several 
transgenic murine models of autosomal recessive AS have been developed (Cosgrove et 
al. 1996; Lu 1999; Miner and Sanes 1996), but a murine model of XLAS has not 
(Kashtan 2002). However, several forms of AS have been identified as spontaneous 
diseases in dogs (Jansen et al. 1984; Hood et al. 1995; Lees et al. 1998; Lees et al. 1999), 
including two forms of XLAS (Jansen et al. 1984; Lees et al. 1999). The first form was 
described in a family of Samoyed dogs, initially reported in 1977 (Bernard and Valli 
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1977), in which partial sequencing of the canine COL4A5 cDNA (GenBank Accession 
no. U07888) subsequently revealed a G-T substitution in exon 35, creating a premature 
stop codon (Zheng et al. 1994). Recently, a second family of mixed-breed dogs with 
XLAS was described (Lees et al. 1999). These Navasota (NAV) dogs, so called because 
of the name of the town from which they originated, exhibited typical clinical, 
histological, immunochemical, and genetic features of XLAS; however, the sequence of 
exon 35 of COL4A5 was normal in affected dogs (Lees et al. 1999).  
Since 1998, a colony of NAV dogs has been propagated at Texas A&M 
University for studies of the pathogenesis and treatment of XLAS. Reported here are the 
full-length coding sequence of canine COL4A5 (GenBank Accession no. AF470624) and 
identification of the frame-shift that is causative for XLAS in NAV dogs. This mutation 
results in the production of a truncated protein lacking most of the collagenous region 
and NC1 domain essential for trimerization. Determination of the sequence of the coding 
region and characterization of the NAV dog mutation will permit construction of a full-
length, wild-type cDNA for COL4A5. This is necessary for utilization of our canine 
model to investigate possible gene transfer therapy for AS.  
 
Materials and methods 
Dogs used in this study were produced within a colony of NAV dogs that is 
maintained at Texas A&M University. Methods of clinical and pathological evaluations, 
including immunofluorescence microscopy to assess α5(IV) chain expression in 
epidermal BM, were as previously described (Lees et al. 1999). Samples of renal cortex 
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obtained at necropsy from normal and affected NAV dogs were snap frozen in liquid 
nitrogen. Tissue was disrupted using Dounce homogenizers (Kontes, Vineland, NJ) and 
the Poly(A)Pure Kit (Ambion, Austin, TX) was used to extract mRNA.  
Gene-specific primers were designed for reverse transcription by using 
Netprimer (Premiere Biosoft, Palo Alto, CA), and gene specificity was assessed using 
the BLAST internet tool (http://www.ncbi.nlm.nih.gov/BLAST/). An enhanced AMV-
RT (Sigma, St.Louis, MO) was used to synthesize cDNA according to the 
manufacturer’s instructions. Both one-step (Clontech BD Bioscience’s Advantage One-
Step RT-PCR kit, Palo Alto, CA) and two-step (Sigma eAMV RT-PCR kit, St. Louis, 
MO and Clontech BD Bioscience Advantage GC2 PCR kit) RT-PCR kits were used to 
amplify cDNAs. 
The sequence for 40% of the 3' end of canine COL4A5 was previously published 
(GenBank Accession no. U07888) and was, therefore, used to design the initial reverse 
transcription primer (COL4A5-NC2-R). All other gene-specific reverse transcription 
primers were designed using the sequence determined for NAV dogs. RT-PCR primers 
COL4A5–E, C, and F were also designed using the published canine COL4A5 sequence. 
For amplification of the 5' portion of the cDNAs, the published sequence of the human 
cDNA (GenBank Accession no. NM_000495) was used to design sense primers. Data 
derived from sequencing of the 3' fragments were used to design canine-specific 
antisense primers. Each subsequent primer pair contained one human and one canine-
specific primer (Table 4).  In order to maximize both gene specificity and cross-species 
amplification, touchdown protocols were used for most PCRs.  In this method a high 
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temperature is used for the initial annealing step, and the temperatures is decreased one 
degree per cycle to a target temperature at which the remainder of the cycles take place.  
Standard thermocycling protocols were used for amplification of two fragments 
(COL4A5-J and COL4A5-Q+).  All annealing temperatures are reported in Table 4.  
Amplification products of expected sizes were cloned into pCR2.1 (Invitrogen, 
Carlsbad, CA), and were transformed into chemically competent E. coli JM109 
(Promega, Madison, WI) or DH5αMCR cells (GibcoBRL Life Technologies, Carlsbad, 
CA).   Plasmid DNA was isolated  and sequencing reactions were carried out with the 
dye termination method and resolved on the 373XL and 377XL automated sequencing 
machines (PE Biosystems, Foster City, CA). Assembly of contiguous fragments, 
alignment, and sequence analysis were carried out using Vector NTI Suite II (Informax, 
Bethesda, MD) software.  
Total RNA was isolated from canine peripheral leukocytes using the RNA Blood 
Module, RNAqueous, and Poly(A)Purist Kits (Ambion). Because the large introns of 
canine COL4A5 have not been sequenced, the primeres were designed to amplify the 
cDNA on either side of the mutation site.  Nested RT-PCR was performed on mRNA 
reverse transcribed using COL4A5-RevT-5, by using the primer set COL4A5-Q+ and 
amplified with the Advantage GC-2 RT-PCR kit (Clontech BD Bioscience). An aliquot 
of that product was subsequently reamplified, with the COL4A5-AS1 set of fluorescently 
labeled primers, in which the sense primer was labeled with 6-FAM (Sigma Genosys, 
The Woodlands, TX). Fragments were resolved on the ABI 310 capillary-based Genetic 
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Analyzer (PE Biosystems) and analyzed using the Genotyper 2.0 software (PE 
Biosystems). 
 
 Table 4.  COL4A5 primer sets. 
Name 
Size 
(bp) 
Location 
(to 
human: 
NM_ 
033380) 
Anneali
ng 
Temp. 
('C) for Sequences 
COL4A5-S-F/R 316 
F: 43 
R: 359 55-52 RT-PCR 
S-F:TTCTTCCACTCTTAAAAAGC                                  
S-R:GAAATCCTCTCTCCCCCT 
COL4A5-Q-F/R 695 
F: 207        
R: 902 63-60 RT-PCR 
Q-F:AACTGCGTGGAGTCAGCCTGG                         
Q-R:GACCTTGCTCACCTTTTTCACCTTTG 
COL4A5-P-F/R 470 
F: 696        
R: 1166 63-57 RT-PCR 
P-F:CACTGCCAGGACCAAAGGGTAATC                  
P-R:CAGGGTAACCAGGATCACCAGGTAAAC 
COL4A5-M-F/R 488 
F: 1074      
R: 1562 63-59 RT-PCR 
M-F:AAGGAGAGCCAGGCAAAAGAGGTA               
M-R:CTGTTTCACATATCTCATCACTAGGAGAGA 
COL4A5-5'-
F5/R4/5 629 
F: 1303      
R: 1932 65-58 RT-PCR 
F5:TGGAGAAAAAGGAGAGCGAGGATT   
R4/5:GTGCCAGGTAAACCAGGAAGCC   
COL4A5-J-F/R 378 
F: 1756      
R: 2132 65 RT-PCR 
J-F:ACATGCTGGTCTAACAGGTCCCAAAGGATTA 
J-R:CTGGATTTCCTGCCACACCTTGTATGCC 
COL4A5-H-F/R 547 
F: 2099      
R: 2646 71-64 RT-PCR 
H-F:GGAAAAAGGCATACAAGGTGTGGCAGGA 
        AATC 
H-R:AGCCCAGGAGGTCCCATTGGTCCAGGTT 
COL4A5-G-F/R 754 
F: 2515      
R: 3269 65-58 RT-PCR 
G-F:TGGTCCAAAAGGTGATCGTGGTTTCC                
G-R:GAGGTCCTGTAAGCCCTGGTTTCCC 
COL4A5-F-F/R 316 
F: 3211      
R: 3527 66-63 RT-PCR 
F-F:ACCATCAGGTCCCAAAGGTAACCCCG                
F-R:TAATCCAGGCAAACCAGTATCTCCCATA 
       GAAC 
COL4A5-C-F/R 968 
F: 3494      
R: 4462 66-63 RT-PCR 
C-F:GTTCTATGGGAGATACTGGTTTGCCT 
        GGATTAC 
C-R AGGGAGTCCGTTGCGTCCTGGAT 
COL4A5-E-F/R 572 
F: 4199      
R: 4771 68-63 RT-PCR 
E-F:GGTGTTCCAGGATTTCCAGGTATGAAGGGAC 
E-R:AGGCATGGTACTGAAGCGACGAAGGCAACT 
COL4A5-NC2-F/R 571 
F: 4670      
R: 5241 63-57 RT-PCR 
NC2-F:ATTTATGAAGGCTTTTCTCTCTTATATGTCC
NC2-R:CGTGTCCTCAAGTCTCCTGCTTTC 
COL4A5-T-F/R 500 
F: 5189      
R: 5689 64-59 RT-PCR 
T-F:ATATGTTCAGCAAACCTCAGTCAGAAAC          
T-R:GGATACAGCAGGATTAGTAGCACCG 
COL4A5-Q+-F/R 592 
F: 573      
R: 941 60 RT-PCR 
Q+-F:GCAATGGAACCAAGGGAGAACG 
Q+-R:AGGGTAACCAGGATCACCAGGTAAAC 
COL4A5-AS1-F/R 
252/ 
242 
F: 687 
R: 940 58-56 RT-PCR 
AS1-F:ATTATGTCATCACTGCCAGGA 
AS1-R:GTTCACTGATCTGCCCAGG 
COL4A5-RevT-1   3809-3838  GSP-RT AATGCCAGGTAATCCTCCATCACCCTTTTGAC 
COL4A5-RevT-2   3737-3770  GSP-RT CAAAGCCTGGTTGACCTGGTTCACCCTTCTGTCC 
COL4A5-RevT-3   2660-2689  GSP-RT AATCCCTGGTGGTCCTGGTGGTCCCTGAAC 
COL4A5-RevT-4   2768-2795  GSP-RT GACTGCCTCTTTCACCTGGGGGTCCTGG 
COL4A5-RevT-5   1607-1641  GSP-RT 
GTGTCACCTTTGTCACCTTTCACTCCTT 
GTTCTCC 
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Results  
Sequencing of canine COL4A5 cDNA and determination of the causative mutation 
Previous work demonstrated an X-linked pattern of disease transmission and 
absence of type IV collagen α5 chains in the GBM of affected NAV dogs (Lees et al. 
1999). Thus, an examination of COL4A5 as a candidate gene was warranted. To do this, 
cDNA of COL4A5 was synthesized from normal and affected dogs. Amplification of the 
entire coding sequence was difficult because the collagenous region has an unusually 
high GC level. This promotes formation of secondary structures during reverse 
transcription (RT), PCR, and subcloning. For example, rearrangements and deletions of 
amplicons occurred in recombination-deficient Escherichia coli (i.e., INVα, TOP10) 
strains. Therefore, JM109 and DH5αMCR strains of E. coli were used for propagation of 
constructs harboring segments of COL4A5. A second complicating factor is that the 
conservation of nucleotide sequences among members of the collagen gene super-family 
is very high, particularly in the collagenous region. This necessitated the use of gene-
specific RT and PCR primers.  Therefore, in order to capture the entire coding region of 
COL4A5, 13 overlapping fragments were amplified (Table 4). The smallest fragment 
amplified is 316 bp (COL4A5-F, COL4A5-S) while the largest is 968 bp (COL4A5-C) 
(Table 4). This sequential approach allowed determination of the complete sequences of 
the COL4A5 cDNAs from multiple normal (GenBank Accession no. AF470624), and 
affected NAV dogs and includes the 5' and 3' UTRs. The BLAST internet tool was used 
to compare each of the fragments with the published partial canine COL4A5 (GenBank 
Accession No. U07888) and full-length human COL4A5 (GenBank Accession no. 
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NM_000495) sequences to verify that the amplicons were indeed COL4A5.  
Additionally, there was sequence consensus between areas of overlap for each fragment.  
The characteristic motifs of type IV collagens are present, including the globular 7S 
amino terminus, a long, conserved collagenous region with multiple interruptions 
(Pihlajaniemi et al. 1990), and the NC1 region.  The sequence of the normal canine 
COL4A5 has 93% identity to human, and the deduced open reading frame has 94% 
identity. 
Comparison of the sequences of the normal and affected dogs revealed a 10 bp 
deletion in the putative exon 9 (as deduced from sequence information for human 
COL4A5) of COL4A5 from dogs with XLAS (Figure 2). To confirm this mutation, this 
primer set (COL4A5-Q) was also used to amplify the same region from a total of ten 
normal and ten affected dogs, as well as an unrelated dog (a female Dalmatian). 
Sequence analysis revealed that the mutation segregated with XLAS affected dogs. As 
expected, when this region was amplified and sequenced from five carrier females, 
analysis revealed that approximately half of the transcripts harbored the mutation, while 
half were normal (data not shown).  
This frame-shift mutation disrupts the amino acid Gly-X-Y collagenous domain 
repeat and results in a premature stop codon in putative exon 10 (Figure 2). This 
mutation is different from that described for Samoyed dogs (Zheng et al. 1994) and 
causes elimination of 85% of the carboxyl terminus. This results in the absence of the 
majority of the collagenous region and the entire NC1 domain. Because these are  
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necessary for trimerization of the collagen peptides, it is not surprising that the 10 bp 
mutation is so deleterious.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 2. Nucleotide and amino acid sequences for COL4A5 exons 9 and 10. This shows the   
deletion, resulting frame-shift and premature stop codon, as determined in normal and affected 
male Navasota dogs with XLAS.  A 10 bp deletion in exon 9 causes XLAS in NAV dogs.  
 
 
Genetic test 
Prior to work reported here, identification of dogs destined to develop XLAS was 
accomplished using immunofluorescence microscopy of skin biopsy specimens to assess 
expression of α5(IV) chains in the epidermal BM of one-week-old puppies.  
Immunostaining of α5 chains in epidermal BM has a uniform linear pattern in normal 
males and females, has a discontinuous linear (mosaic) pattern in carrier females, and is 
absent in affected males (Lees et al. 1999).  Characterization of the mutation responsible 
for canine XLAS allowed for the development of a PCR-based test of COL4A5 cDNA  
       E  P  G  S  I  I  M  S  S  L  P  G  P 
Normal GAACCAGGTAGTATAATTATGTCATCACTGCCAGGACCA 
XLAS   GAACCAGGTAGTATAATTATGTCATCACTGCCAGGACCA 
       E  P  G  S  I  I  M  S  S  L  P  G  P 
 
K  G  N  P  G  Y  P  G  P  P  G  I  Q    
Normal AAGGGTAATCCAGGATATCCAGGTCCTCCTGGAATACAA 
XLAS   AAGGG----------TATCCAGGTCCTCCTGGAATACAA 
       K  G            I  Q  V  L  L  E  Y  K  
   
       G  P  A  G  P  T  G  L  P  G  P  I  G   
Normal GGCCCAGCTGGTCCCACTGGTTTACCAGGGCCAATTGGT 
XLAS   GGCCCAGCTGGTCCCACTGGTTTACCAGGGCCAATTGGT 
        A  Q  L  V  P  L  V  Y  Q  G  Q  L  V 
   
       P  P  G  P  P  G  L 
Normal  CCCCCAGGACCACCTGGTTTGA 
XLAS   CCCCCAGGACCACCTGGTTTGA 
        P  Q  D  H  L  V  * 
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that distinguishes between the two alleles (normal and mutant) in NAV dogs. A test 
using genomic DNA has not yet been developed because the small COL4A5 exons (e.g., 
exon 9 is 84 bp) are separated by very large introns, which have not yet been sequenced, 
and are sufficiently different from those in human to prohibit successful primer design 
for amplification. Therefore, peripheral leukocytes were collected for isolation of mRNA 
for subsequent RT-PCR. Although only illegitimate transcripts of COL4A5 are found in 
the leukocytes, sufficient quantities of mRNAs for use in RT-PCR exist. Two sets of 
nested primers were used in this experiment. The product from primer set COL4A5-Q+ 
is used in a subsequent reaction with the primer set COL4A5-AS1 (Table 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Figure 3. Example results of an allele specific test for XLAS in Navasota dogs. The test  
  discriminates carrier females (Adell), normal males (Ned) or females (not shown), and affected males 
  (Newt). 
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The allele present in normal males and females is 252 bp, while affected males have a 
242 bp allele that results from the 10 bp mutation; carrier females are heterozygous 
(Figure 3).  To verify the accuracy of the test, three normal male dogs, three affected 
males, two carrier females, and one unrelated normal dog (a Dalmatian) were genotyped. 
 
Discussion 
The entire canine COL4A5 cDNA was assembled and sequenced.  This analysis 
showed that canine COL4A5 has 93% nucleotide identity to human COL4A5 (GenBank 
Accession no. NM_033380), and an amino acid similarity of 94%. The level of 
conservation was less for murine COL4A5 cDNA (GenBank Accession no. AB041350) 
(i.e., nucleotide identity of 88% and amino acid similarity of 90%). Nucleotide identity 
to the published partial canine 3' COL4A5 cDNA (GenBank Accession no. U07888) was 
99%. 
Interestingly, comparisons of sequences revealed different splicing for the 
previously published canine COL4A5 cDNA (31) and the sequence we report. Two 
transcript variants were originally noted in human COL4A5 cDNAs from kidney and 
leukocytes (Guo et al. 1993). Other studies revealed a total of three transcript variants 
with different tissue-specific expression patterns (Martin and Tryggvason 2001). Two 
previously uncharacterized 9 bp exons were identified in intron 41 and were designated 
exons 41A and 41B (Martin and Tryggvason 2001); each codes for a Gly-X-Y repeat 
(Nakanishi et al. 1994). Human isoform I (GenBank Accession no. NM_000495) is 
found in many tissues, including the kidney, liver, placenta, spleen, and epithelium, and 
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is 18 bp shorter than the full-length transcript, because exons 41A and 41B are skipped. 
The previously published partial canine COL4A5 cDNA (GenBank Accession no. 
U07888), sequenced from renal tissue (Zheng et al. 1994), is orthologous to human 
isoform I. Human isoform II (GenBank Accession no. NM_033380) is the predominant 
form found in the kidney and is also found in the liver, placenta, and spleen. This variant 
uses both exons 41A and 41B, and is most similar to the NAV canine COL4A5 renal 
cDNA sequence reported herein. Human isoform III (GenBank Accession no. 
NM_033381) is expressed solely in epithelium and has only the sequence from exon 
41B. Thus, isoform III is 9 bp different from the aforementioned transcripts. 
The predicted effect of the identified mutation is the production of a truncated 
peptide chain that is unable to participate in post-translational, extracellular assembly in 
type IV collagen networks.  In XLAS, the α3 and α4 chains are usually absent from the 
GBM (as determined by immunostaining), even though their genes are intact (Nakanishi 
et al. 1994; Knebelmann et al. 1996; Kalluri et al. 1997; Heidet et al. 2000). This is 
thought to be due to failure of the proper assembly of stable α3/α4/α5 trimers. Not all 
mutations that result in the production of a defective α5 chain prevent formation of an 
α3/α4/α5 trimer (Kalluri et al. 1997); although such trimers are not fully functioning 
proteins. Upon secretion, these defective trimers are subject to extracellular degradation, 
since they are unable to form a stable supramolecular network (Kalluri et al. 1997). 
Mutations that produce truncated α5 chains lacking the noncollagenous 1 (NC1) domain 
prevent trimerization, resulting in the intracellular degradation of the α3 and α4 chains 
(Kalluri et al. 1997). Production of truncated α5(IV) chains that cannot form stable 
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networks is consistent with negative immunostaining for α5(IV), α3(IV) and α4(IV) 
chains in the GBM of affected NAV dogs (Zheng et al. 1994), as well as the absence of 
α5(IV) and α6(IV) chains in the epidermal BM of affected dogs (Lees et al. 1999).  
Both canine models of XLAS (NAV and Samoyed) have premature stop codons 
(Zheng et al. 1994) and fall into the “truncated protein” group of mutations, which 
includes premature stop codons, frame-shifts, and large rearrangements. The production 
of truncated α5(IV) chains preventing formation of the COL4A3/COL4A4/COL4A5 
network in GBM is consistent with the severe disease phenotype and early onset of renal 
failure observed in affected dogs (Lees et al. 1999), as well as humans (Gross et al. 
2002). The clinical presentation of AS in these dogs is analogous to Type-S (severe) 
designation (Gross et al. 2002) in which juvenile onset of ESRD is found in 92% of 
human patients. Similarly, both canine models have early onset of proteinuria (3-6 
months in the NAV, 4 months in the Samoyed) and juvenile ESRD (6-18 months in the 
NAV, 8-10 months in the Samoyed) (Kashtan 2002). 
Previously, identification of dogs destined to develop XLAS was accomplished 
with immunofluorescence microscopy of skin biopsy specimens to assess expressino of 
α5(IV) chains in the epidermal BM of 1-week-old puppies.  Immunostaining of α5 
chains in epidermal BM has a uniform linear pattern in normal males and females, has a 
discontinuous linear (mosaic) pattern in carrier females, and is absent in affectecd males 
(Lees et al. 1999).  However, although accurate (100%) in males, it can be inaccurate in 
heterozygous females owing to Lyonization,  thus potentially leading to misclassification 
of some carrier females as genetically normal individuals. The allele-specific test 
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overcomes this problem by examining COL4A5 at the genetic, rather than the protein 
levels. RNA extracted from peripheral leukocytes may be used for genetic tests on NAV 
pups, facilitating the identification of XLAS affected and carrier dogs. 
In summary, the sequence of the canine COL4A5 cDNA is reported, and the 10 
bp deletion in COL4A5 causative for XLAS in NAV dogs has been identified. 
Characterization of this mutation has allowed development of an allele-specific PCR test 
to identify dogs in this kindred destined to develop XLAS. This will (1) allow the rapid 
identification of NAV dogs destined to develop XLAS and (2) complement the use of 
skin biopsies for diagnosis. Availability of the complete cDNA sequence for COL4A5 
facilitates production of a full-length, wild-type cDNA suitable for gene transfer therapy 
trials, which might ultimately lead to gene therapy-based treatments for AS in humans.
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CHAPTER V 
GENE EXPRESSION ANALYSIS IN A CANINE MODEL OF X-LINKED 
ALPORT SYNDROME 
 
Overview 
A kindred of mixed-breed dogs with an inherited nephropathy that is clinically, 
morphologically, and genetically similar to human XLAS has been identified.  A 
nonsense mutation in COL4A5 causes XLAS in this kindred (Cox et al. 2003). Kidneys 
from unaffected dogs within the kindred are histologically normal, whereas renal sections 
from dogs with XLAS have abnormalities typical of chronic progressive renal disease 
secondary to protein-losing glomerulopathy. Lesions in affected kidneys include 
progressive glomerular sclerosis with capsular fibrosis, interstitial fibrosis with mixed 
mononuclear cell inflammation, tubular atrophy, tubular dilation, and tubular proteinosis 
with intraluminal casts. Transcriptional profiling of renal cortex from dogs with advanced 
renal dysfunction resulting from XLAS and related, normal dogs of similar ages was 
performed using a canine oligonucleotide array, and the results revealed marked 
differences in gene expression that correlated with the morphologic changes present in 
kidneys from XLAS-affected dogs. At the transcriptional level, approximately 1,200 
genes were differentially expressed (i.e., differences greater than 2-fold) in kidneys of 
affected dogs compared with controls. Quantitative RT-PCR (Q-RT-PCR) confirmed the 
expression profiles of 14 clinically interesting genes. Differences in levels of expression 
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were consistent with observed histological findings of chronic inflammation and fibrosis, 
as evidenced by the marked up-regulation of inflammatory mediators (e.g., gp80, MCP-
1), interstitial collagens (COL1A1 and COL1A2) and matrix remodeling proteins (e.g., 
TIMP-1). The strong correlation between pathological changes and differences in gene 
expression further characterizes this canine model of XLAS and enhances its utility for 
studies of disease progression and therapy. 
 
Introduction 
Alport syndrome is an hereditary progressive renal disease first described in the 
human (Alport 1927).  AS is caused by mutations in genes that encode three of the type 
IV collagens, which are essential structural components of basement membranes found in 
the glomerulus of the kidney, the cochlea, and the cornea. Perturbation of these different 
basement membranes occasionally leads to hearing loss and ocular abnormalities along 
with renal disease (Kashtan 1998; Tryggvason and Martin 2001). Type IV collagens are 
members of the collagen superfamily, which at latest count includes more than 40 
members in 27 subfamilies (Pace et al. 2003). Collagens are triple-helical proteins 
consisting of three alpha chains that contain (Gly-X-Y)n repeats, with glycine being the 
only amino acid small enough to fit into the center of a triple helix. Interruptions in the 
collagenous domains of the type IV collagens allow flexibility of the triple helix, 
permitting the heterotrimers to form a characteristic lattice-like network. Also important 
for assembly of the network are the carboxyterminal noncollagenous (NC1) domain and 
the aminoterminal noncollagenous (7S) domain. Of the six type IV collagen chains, the 
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COL4A1 and COL4A2 chains are present in all basement membranes, and the remaining 
alpha chains have varying distributions (Miner 1999). The interactions of collagens and 
other proteins are vital, because mutations in genes encoding collagens are responsible 
for many hereditary diseases. Some of these diseases (e.g., Alport syndrome and Ehlers 
Danlos syndrome) have also been described in the dog and result from mutations in the 
canine collagen orthologs (Freeman et al. 1987; Zheng et al. 1994; Rodriguez et al. 1996; 
Lees et al. 1999). 
XLAS in the dog was first described in a Samoyed kindred (Bernard and Valli 
1977). Partial sequencing of the cDNA for COL4A5 (GenBank Accession Number 
U07888) in these dogs revealed a G-T substitution in exon 35, creating a premature stop 
codon (Zheng et al. 1994). A family of mixed-breed dogs (termed Navasota, abbreviated 
NAV) with XLAS was also described (Lees et al. 1999). NAV dogs exhibit typical 
clinical, histological, and immunochemical features of XLAS, and the disease is 
transmitted in X-linked fashion. When molecular analysis was performed, it was found 
that NAV dogs with XLAS have a normal sequence in exon 35 of COL4A5 (Lees et al. 
1999).   Upon further analysis, it was determined that these dogs have a 10 bp deletion in 
exon 9 (of 51), causing a premature stop codon in exon 10 (Cox et al. 2003). The 
collagen protein is therefore truncated, resulting in a severe disease phenotype of ESRD 
at an average age of 11 months (Cox et al. 2003). 
Our long-range goal is to understand the genetic factors underlying the 
nephropathy that accompanys cellular and molecular events in AS and generalized 
ESRD. Chronic renal failure is a common cause of death in the dog, and few models 
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(Brown et al. 2003) exist to allow the identification of biomarkers and mechanisms of 
secondary renal disease. Since all ESRD is characterized by the loss of cells and their 
replacement by inflammatory cells, fibroblasts, and extracellular matrix (Ying et al. 
2001), the NAV dogs can be used to evaluate generalized progressive renal failure at the 
molecular level. 
Many techniques have been developed to examine levels of gene expression, and 
DNA microarrays permit comprehensive study of global gene expression in many disease 
models. Microarrays are of great use in the study of nephrology (Hsiao et al. 2000; 
Hayden et al. 2003), including the opportunity to clarify molecular mechanisms of 
normal or disturbed organ or cellular function, and studies of these types have been 
carried out in the human and the mouse (Sarwal et al. 2003; Yuan et al. 2003). For a 
robust study of the dog, however, a canine-specific microarray platform is necessary. A 
proprietary, canine-specific Affymetrix GeneChip oligonucleotide array (liCanine1a) 
with 22,774 probe sets (13,729 derived from canine sequences and 9,045 derived from 
human sequences) has been developed and validated by Eli Lilly and Company (Higgins 
et al. 2003). This array will facilitate the identification of genetic events that underlie 
disease mechanisms and will provide insight regarding the progression of disease in our 
NAV model of XLAS. Use of the microarray will also allow identification of candidate 
genes of interest as biomarkers, genes expressed in attempted compensation by the 
kidney, and genes involved in tubulointerstitial scarring that are shared by end-stage 
XLAS nephropathy and generalized ESRD due to other causes. 
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Materials and methods 
The NAV dogs are maintained at Texas A&M University, and studied according 
to protocols approved by the Texas A&M University Laboratory Animal Care Committee 
protocols. Seven related males, four affected dogs and three age-matched normal dogs 
were chosen for this study. Routine clinical and pathological evaluations were performed 
and tabulated as previously described (Lees et al. 1999). Affected dogs were sacrificed 
when a standardized end-point was reached, as determined by clinical parameters. Renal 
cortex samples obtained at necropsy were snap frozen and total RNA was isolated from 
100 mg of each sample using RNA Stat60 (TelTest, Friendswood, TX) according to 
manufacturer’s protocol. The isolated total RNA was further purified with Qiagen’s 
RNeasy system (Valencia, CA). For reverse transcription, SuperScript II (Invitrogen, 
Carlsbad, CA) together with an oligo T-7-(dT)24 primer (Operon, Valencia, CA) was 
used to reverse transcribe 12 µg total RNA for each sample. The cDNA was purified and 
the BioArray T-7 polymerase labeling kit (Enzo, Farmingdale, NY) was used to 
synthesize biotinylated cRNA, according to manufacturer’s instructions. Biotinylated 
cRNA was purified and fragmented using the GeneChip Sample Cleanup Module 
(Affymetrix, Santa Clara, CA) prior to overnight hybridization with the canine 
microarray (liCanine1a). Arrays were washed and stained according to the Affymetrix 
eukaryotic expression sample protocol (Affymetrix GeneChip Expression Analysis 
Technical Manual). Microarray Suite (MAS) 5.0 and Data Mining Tool (DMT), 
Affymetrix-based software packages, were used to perform data analysis. 
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  To confirm transcriptional changes detected by the canine microarray, a subset of 
14 clinically interesting transcripts were selected for quantitative real-time PCR. Gene 
specific primers, as listed in Table 5, were designed using Primer Express 1.5 (Applied 
Biosystems, Foster City, CA). Total RNA was isolated from kidney cortex of normal 
(n=3) and XLAS affected dogs (n=4) as previously mentioned. The RNA (3.2 µg) was 
DNase treated (DNA-free, Ambion) and reverse transcribed using Omniscript reverse 
transcriptase (Qiagen). Primer specificity and amplicon size was confirmed by 
electrophoresis through 4% agarose prior to quantitative fluorescence-based detection 
using the Applied Biosystems Prism 7900HT® Sequence Detection System. Reactions 
contained 100 µM forward and reverse primer, SybrGreen™ PCR Master Mix (Applied 
Biosystems), and cDNA template. Each assay was performed in triplicate and the PCR 
parameters were: 50ºC, 2 minutes followed by 95ºC, 10 minutes. These pre-
amplification temperatures were followed by 40 cycles of 95ºC, 15 seconds and 60ºC, 1 
minute. Data were analyzed by the comparative threshold (Ct) method of relative 
quantitation. All values are expressed as fold change (calculated from the signal log 
ratio) compared with the control group. 
 
Results 
Screening of the 22,774 probe sets (not all are unique due to overlap among 
proprietary, canine, and human sequences represented on the array), revealed 
approximately 1,200 genes that are differentially expressed (i.e., greater than 2-fold). 
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Obviously, only a subset of these can be shown herein (Table 6). To reduce the 
proportional error between random noise and signal intensity, the signal log ratio (SLR),  
 
Table 5.  Primer sequences for genes amplified by Q-RT-PCR. 
Gene Accession 
Number 
Primer Sequence (5'-3') 
F: CCCTTGAACACGCATGACATC MMP-9 AF169244 
R: GTCCACCTGGTTCACCTCATTC 
F: CCTCCAGATTGCGGAGAAGTT GP80 BI395936 
R: CAGGGAGGACGTGTTGAACAT 
F: ATTCTTGGAAAGAAATGGCTTCCT VCAM-1 CFU32086 
R: GCCTATTTTTCAGGCAGAAAGTTTT 
F: ACTGCAGAGTGACACTCACTGCTT TIMP-1 AF077817 
R: TGGCGGCTCTGGAAACC 
F: GGATCCACTGTCTGGATATTAATGAG EGF AB049597 
R: TGCAGGTATAGTTTCCCTCCATATT 
F: GCCGCTTCACCTACAGTGTCA COL1A1 AF153062 
R: GAGGTCTTGGTGGTTTTGTATTCG 
F: CATGCTCAGCTTTGTGGATACG COL1A2 AF035120 
R: GCAGTTGCCTCCTGTAAAGATTG 
F: TGTTCCCCCCATGAAGCTACT APOA2 Proprietary 
R: GCACAAAAGCCCCTTCGA 
F: TTGGTAGCCAGGAAAATTCTGAA OSTEO 
PONTIN 
Proprietary 
R: ACAATTAACTCCTTCTCATGGCTTTG 
F: TGCAACATCAACAACGTGTGTAA COL4A1 CFU50933 
R: GGCTCCGGCGTGGATAG 
F: TGTACTGCAACCCTGGTGATG COL4A2 CFU50934 
R: AGTGGTGGACAGCCAGTAGGA 
F: TGGAGCCTTATATTAGCAGATGCA COL4A3 CFU50935 
R: AATGTCAGTGGTTTGGCTGTGA 
F: TTGGTCTGGCAGGGTCTTG COL4A4 CFU50936 
R: TGGCACACTTGGTGGATGTT 
F: CCCAGGATGCAACGTCTCA COL4A5 AF470624 
R: TCTCTTGGTCATATATAGTAGCACCA 
     TTG 
F: GCCCCGCTTTAGCACCAT COL4A6 CFU50937 
R: TCATTGCGTCTGGCGTAGTG 
F: CGGATTTGGCCGTATTGG GAPDH AB038240 
R: GATGGCGACAATATCCACTTTG 
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Table 6. Analysis of microarray data: Example of genes identified as up- or 
 down- regulated in affected NAV dogs as compared with normal siblings. 
Genes up-regulated in affected dogs 
Extracellular 
Matrix 
Inflammato
ry cell 
Response 
Cellular 
Matrix/ 
Structural 
Metabolism/ 
Signalling 
Protein 
Transport 
Stress 
Response 
MMP-9 MHC class 
II genes 
dynamitin selenophosphate 
synthetase 
CK2 
interacting 
protein 1 
MAPKAPK3 
decorin IgG heavy 
chains 
NADPH phospholemman integral 
type I 
protein 
(P24B) 
 
TIMP-1 ApoE actin cross-
linking 
factor 
L-asparaginase AP3B1  
COL1A1 complement 
c3 precursor 
claudin-2 HMGCL   
COL1A2  IgA heavy 
chain 
tubulin DLST   
COL4A1 A3 
adenosine 
receptor  
SH3 domain 
protein 
UBE2M   
osteopontin midkine 
precursor 
Rho-1 dipeptidyl 
peptidase I  
  
 IL-6  S-100 protein   
 MCP-1     
Genes down-regulated in affected dogs 
Cell 
proliferation 
Metabolism/ 
Signalling 
    
EGF isovaleryl 
CoenzymeA 
dehydrogenase 
    
IGFBP2 kallikrein     
 PDEA     
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Table 7. Analysis of microarray data: Average fold changes of 10  
genes up-regulated in affected dogs. 
Gene Fold change Standard deviation 
gp80 25.21 1.4363 
MCP-1 11.18 1.7545 
COL1A1 10.88 1.4353 
Osteop 10.1 1.5685 
COL1A2 5.82 1.4833 
Rho-1 3.54 1.3066 
Decorin 3.44 1.8017 
Tubulin 2.97 1.9485 
SH3  2.5 1.2805 
COL4A1 2.17 1.7296 
 
 
was used to calculate the average of all possible combinations of normal and affected 
dogs. Fold change (FC) was calculated by taking the arithmetic mean of all of the 
individual SLRs and raising the resulting number to the power of 2, effectively reversing 
the log transformation for reporting purposes. Standard deviations were calculated to 
determine how widely the values varied (Table 7). If it was not possible to calculate FC 
due to lack of signals in either all normal or all affected dogs, genes were categorized as 
increased or decreased in affected dogs as compared to normal siblings (Table 6). A 
conservative estimate of genes was used to ensure statistical significance. That is, only 
those genes that were expressed in all 3 normal dogs, and/or all 4 affected dogs, were 
tabulated.  Relative fold changes of several of these genes are shown in Figure 4. 
A subset of 14 clinically interesting genes was chosen for validation by 
quantitative RT-PCR. Signal intensity values were first normalized to the GAPDH 
standard and then down-scaled to normalize the values against a normal control dog. 
Following this, FC was calculated by raising the negative of the resulting number to the 
power of 2. The 14 genes chosen for Q-RT-PCR analysis included several categorized as 
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up-regulated (gp80, VCAM-1, TIMP-1, COL1A2, COL1A1, Osteopontin, and COL4A1), 
one that was down-regulated (EGF), one that was unchanged (ApoA2), and five that 
were non-hybridizing, but of special interest (COL4A2-COL4A6). 
 
 
Figure 4.  Analysis of microarray data: Average fold change of selected genes in affected 
NAV dogs. 
 
 
 The 2-ddCt method of quantification was used to analyze the Q-RT-PCR results 
(Livak and Schmittgen 2001). In order to establish an internal control, both 18S rRNA 
and GAPDH genes were amplified and compared to the genes of interest over a serial 
dilution of cDNA. The dCt varies with target dilution, and if the efficiencies of the 
targets and reference genes are similar, the reference gene may be used as a standard for 
those genes (Livak and Schmittgen 2001). In this case, GAPDH most closely matched 
the efficiencies of the genes of interest (data not shown), and was used as the internal 
control. Samples were run in triplicate, and after normalization to GAPDH and 
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calibration to an untreated control sample (a normal sib), the mean, standard deviation 
and fold change were calculated for all genes of interest. 
All 14 genes assessed by Q-RT-PCR amplified well (Figure 5). 
 
 
Figure 5. Q-RT-PCR data: Gene expression (by fold change) of normal and affected NAV 
dogs. 
 
 
 
The 9 genes represented by working probe sets on the microarray confirmed the trends 
observed in hybridization to the microarray. Five of these transcripts are compared in 
Figure 6. Since the type IV collagens generally did not hybridize well to the chip, and 
they are of great interest in this disease model, all type IV collagens were subjected to Q-
RT-PCR. COL4A1 and COL4A2 showed a very modest up-regulation in affected dogs, 
but the expression levels of COL4A3, COL4A4, COL4A5 and COL4A6 were not 
statistically significantly different between normal and affected dogs (Figure 7). 
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
gp
80
VC
AM
-1
TIM
P-
1
EG
F
CO
L1
A1
CO
L1
A2
Ap
oA
2
Os
teo
p
CO
L4
A1
CO
L4
A2
CO
L4
A3
CO
L4
A4
CO
L4
A5
CO
L4
A6
G enes of In terest
Fo
ld
 C
ha
ng
e
N orm al_02E
N orm al_02F
N orm al_01I
X LAS _02B
X LAS _02D
X LAS _01D
X LAS _01J
 65
Figure 6.  Q-PT-PCR and microarray data: Average fold change of up-regulated genes in 
affected NAV dogs. 
 
Figure 7. Q-RT-PCR data: Fold change of type IV collagens in normal and affected NAV 
dogs. 
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Discussion 
 
Profiling the genome using microarray analysis allows examination of the 
molecular, pathologic and physiologic pathways of XLAS and hopefully those pathways 
common to ESRD regardless of the original inciting cause. Hence, this work will help 
reveal the involvement of known and unknown regulatory pathways of end-stage XLAS, 
and how these pathways differ in the kidney of normal and affected dogs. While the 
clinical features and histopathology of this disease are well described, these pathways 
are poorly understood, and can best be elucidated by such a platform.  
Background noise in microarray data is a well-documented problem, particularly 
when samples are genetically heterogeneous; however, a sufficiently large sample size, 
sound experimental approach, and statistical analysis can offset these variables. Another 
difficulty in interpreting such data is that signal intensity may vary depending on sample 
preparation and individual chips. To minimize such variables, sample preparation was 
kept consistent, and microchips from the same batch were used on all samples. 
The microarray used was previously described and validated in an analysis of 
acute phase response to lipopolysacchride (LPS) challenge in canine kidney (Higgins et 
al. 2003). Not surprisingly, more genes were up-regulated in the affected NAV dogs as 
compared to normal siblings than were down-regulated. This reflects the disease state, in 
which genes that are not normally expressed are turned on (e.g., as part of the 
inflammatory cell response), and those that are generally at a low working level (e.g., 
genes encoding proteins that are part of extracellular and cellular matrix remodelling) 
are up-regulated. The degree of tubulointerstitial nephritis in this canine model is 
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confirmed by the inflammatory cell response of up-regulated cytokine, chemokine, and 
MHC genes activated in the renal cortex. This inflammatory response creates further 
damage in the kidney (Ikezumi et al. 2003; Matsuo et al. 2003). Histologically, XLAS- 
affected kidneys in this study showed mixed mononuclear cell inflammation (mainly in 
the tubulointerstitium) along with other markers typical of chronic inflammation and 
fibrosis.  
Expression of the type IV collagens as assessed by Q-RT-PCR confirm those 
reported from studies of the human. In contrast, an earlier study of the Samoyed XLAS 
dog, (Thorner et al. 1996) it was suggested that expression of COL4A3, COL4A4 and 
COL4A5 was down-regulated, relative to normal controls. It was hypothesized this may 
indicate pretranscriptional co-regulation of all 3 genes. This has not been found in the 
human (Nakanishi et al. 1996), and we see no evidence of such co-regulation in the 
NAV dog (Figure 8), at least in the end-stage kidney. Finally, other than COL4A1 and 
COL4A2, none of the type IV collagens is significantly differentially expressed in XLAS 
affected dogs. COL4A1 and COL4A2 make up the embryonic GBM before the isotypic 
switch occurs in glomerular development (Miner 1998). It is logical that they are 
somewhat upregulated in the absence of the normal COL4A3/COL4A4/COL4A5 
network, in an attempt to compensate for this missing structure (Kalluri et al 1997; 
Harvey et al. 1998), This is also consistent with the observations that expression of these 
genes as assessed by immunofluorescence in both the glomerulus and tubulointerstitial 
compartments is up-regulated (data not shown). 
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Extracellular matrix proteins are highly up-regulated in XLAS affected dogs. 
Seven known extracellular matrix genes are over-expressed, while none are called as 
under-expressed, consistent with the role of cortical fibrosis in the progression of 
disease. Extracellular proteoglycans are not differentially expressed, but the synthesis 
and turnover of extracellular matrix are demonstrated by the up-regulation of the type I 
collagens (COL1A1 and COL1A2), two type IV collagens (COL4A1 and COL4A2), as 
well as matrix metalloproteinases (MMP-9), TIMP-1, decorin, and osteopontin. A 
previous study assessing changes in matrix metalloproteinases showed MMP-9 to be up-
regulated in affected NAV dogs as compared to their normal sibs (Rao et al. 2003), 
which is corroborated by the data presented herein. 
 Monocyte chemoattractant protein-1 (MCP-1) and osteopontin (SPP-1) are 
chemokines that have been implicated in macrophage-mediated renal injury (Pichler et 
al. 1994; Hao et al. 2003; Ikezumi et al. 2003), and their up-regulation in affected NAV 
dogs is not unexpected. Surprisingly, neither TGF-β nor endothelin (ET-1) are 
differentially expressed, as assessed by multiple probe sets on the microarray. This is 
unexpected because TGF-β1 is known to induce the synthesis of extracellular matrix 
proteins such as fibronectin and collagen (Noh et al. 1993; Goumenos et al. 2001; Strutz 
et al. 2002) and to play a role in glomerular damage and tubulointerstitial fibrosis 
(Sayers et al. 1999; Abbate et al. 2002). 
ET-1 is a potent vasoconstrictor normally produced by glomerular epithelial cells 
and monocytes.  This protein stimulates monocyte proliferation and increased expression 
of the collagens and fibronectins. ET-1 stimulates collagen matrix reorganization in 
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monocyte α1β1-integrin-mediated migration and MMP-2 activity (Boffa et al. 2001), 
causing collagen remodelling in progressive glomerulonephritis. ET-1 is not 
significantly differentially expressed according to microarray analysis, although the type 
I collagens, which it is known to activate, are significantly up-regulated. Additionally, 
there was only one probe set for MMP-2 present on the chip, to which only one of the 7 
samples hybridized; therefore, we conclude that this probeset was not adequate to give a 
true representation of the status of MMP-2 in the affected NAV dog. Additionally MMP-
2 mRNA expression as assessed by semiquantitative RT-PCR in another study in these 
dogs showed an average two-fold increase in affected dogs as compared to normal sibs 
(Rao et al. 2003), while MMP-9, which was significantly up-regulated on our chip, 
showed an average increase of 19-fold (Rao et al. 2003). Also, in some models of 
glomerulonephritis, MMP-2 has been found to be of much less importance in the 
development of glomerular injury than MMP-9 (Urushihara et al. 2002).  Also, in a 
murine model of ARAS, MMP-9, but not MMP-2, was up-regulated (Miner and Sanes 
1996). Obviously, the inconclusive evidence regarding these genes in the NAV model 
warrants further investigation. It is likely that by investigating changes in the XLAS 
kidney at stages prior to ESRD (by microarray and Q-RT-PCR) will provide more 
conclusive data on the roles of these genes in the disease process. 
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CHAPTER VI 
DIGGING UP THE CANINE GENOME---A TALE TO WAG ABOUT* 
 
Overview 
There is incredible morphological and behavioral diversity among the hundreds 
of breeds of the domestic dog, Canis familiaris. Many of these breeds have come into 
existence within the last few hundred years. While there are obvious phenotypic 
differences among breeds, there is marked interbreed genetic homogeneity. Thus, study 
of canine genetics and genomics is of importance to comparative genomics, evolutionary 
biology and study of human hereditary diseases. The most recent version of the map of 
the canine genome is comprised of 3,270 markers mapped to 3,021 unique positions with 
an average intermarker distance of ~1 Mb. The markers include approximately 1,600 
microsatellite markers, about 1,000 gene based markers, and almost 700 bacterial 
artificial chromosome-end markers. Importantly, integration of radiation hybrid and 
linkage maps has greatly enhanced the utility of the map. Additionally, mapping the 
genome has led directly to characterization of microsatellite markers ideal for whole 
genome linkage scans. Thus, workers are now able to exploit the canine genome for a 
wide variety of genetic studies. Finally, the decision to sequence the canine genome 
highlights the dog’s evolutionary and physiologic position between man and mouse and  
 
_____________ 
*Reprinted with permission from Greer KG, Cargill EJ, Clark LA, Cox ML, Tsai KL et al. 
(2003) Digging up the canine genome – A tale to wag about. Cytogen Genome Res (in press) 
Copyright S. Karger AG: www.karger.com/cgr 
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its importance as a model for the study of mammalian genetics and human hereditary 
diseases. 
 
Introduction 
The domestic dog has occupied a unique position in human lives for many 
centuries, serving many roles, including: warrior, shepherd, guide, retriever, hunter, and 
companion. Clearly, the dog has many notable behavioral and physical characteristics 
that have been valued over thousands of years. However, the greatest benefit of the dog 
may yet to be realized: its contribution to genetics. 
Recent data suggest the domestic dog’s origin was in East Asia (Savolainen et al. 
2002). Specifically, the common origin of New and Old World dogs from gray wolves is 
demonstrated by mtDNA evidence dating the event to approximately 15,000 to 40,000 
years ago (Leonard et al. 2002). Since its domestication, specific breeds have been 
developed with distinctly different appearances and behavioral traits. The rapid origin of 
breeds has been based on inbreeding a genetic pool composed of a limited founder 
number (Ostrander and Kruglyak 2000). However, the price of limited genetic 
heterogeneity has been the emergence of more than 450 naturally occurring hereditary 
diseases. The small founding populations, high levels of inbreeding and 
creation/maintenance of multigenerational pedigrees have resulted in a population ideal 
for genetic studies because often only a single mutated allele is responsible for these 
diseases (Ostrander and Kruglyak 2000). Furthermore, almost half of the hereditary 
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diseases of the dog have an analogous disease in the human (OMIA 2003). Thus, the dog 
serves as a natural model for study of these diseases and obviates the need to construct 
knockout models for study of such diseases. 
 
Current Status of the Canine Genome 
Mammalian genome comparisons 
Information regarding the canine genome is significantly less than that for the 
murine and human genomes. Determination of the sequences of the human and murine 
genomes confirmed syntenic conservation of genetic loci by pairwise alignment of 
nearly 13,000 orthologous gene pairs. However, the median amino acid sequence 
identity of mouse to human is only 78.5% (Boguski 2002). Thus, human and murine 
comparisons are insufficient to complete our understanding of mammalian gene function 
and evolution. The Mouse Genome Consortium recently noted that many additional 
mammalian genome sequences would be necessary to fully decipher information from 
the human genome sequence. This acknowledgement results from the recognition that 
gene family changes between the murine and human genomes may represent 
physiological divergence from the common ancestor of the mouse and human 
(Waterston 2002). Therefore, because the dog is more closely related, evolutionarily and 
physiologically, to the human than is the mouse, it is an ideal model for comparative 
genetics and will complement information gleaned from sequences of other genomes.  
Mapping the canine genome 
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The dog has 38 autosomes, plus the sex chromosomes. Unfortunately, 
acrocentricity and similarity in the sizes of autosomes complicated standardization of the 
canine karyotype. An international collaboration, DogMap, was established in 1993 to 
create a low-resolution marker map, and to standardize the karyotype. In 1997, sixteen 
linkage groups were derived from the analysis of 94 polymorphic loci (Lingaas et al. 
1997). Shortly thereafter, characterization of 150 microsatellite markers and 30 
additional linkage groups provided the first meiotic linkage map (Mellersh et al. 1997), 
and a framework for development of the 10-centimorgan (cM) map (Neff et al. 1999). A 
map of 341 markers distributed at an average of 9 cM soon followed (Werner et al. 
1999). 
Distinguishing the canine chromosomes with the use of whole chromosome-
specific fluorescent in situ hybridization paint probes (Breen et al. 1999), the 
construction of canine bacterial artificial chromosome (BAC) libraries (Li et al. 1999; 
Schelling et al. 2002), and construction of a radiation hybrid (RH) panel accelerated 
development of a high-resolution map of the canine genome. An initial RH panel was 
constructed (Priatt et al. 1998), and updated by a whole genome RH panel (Vignaux et 
al. 1999). Mellersh and colleagues (2000) integrated the linkage and RH maps, a major 
advance for the study of the canine genome. Maps were integrated through duplicate 
typing of 217 markers, generating an integrated map of 724 unique markers suitable for 
both linkage analysis and comparative mapping. Importantly, integration allowed for 
identification of markers useful in whole genome linkage scans. This subset of markers, 
termed the Minimal Screening Set 1 (MSS-1) (Richman et al. 2001), has been 
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multiplexed to streamline linkage analyses (Cargill et al. 2002). Estimates of genome 
coverage suggest that 77% of the genome is within 1 Mb of at least one marker in the 
MSS-1 (Richman et al. 2001). The most recent RH panel, RHDF5000-2, was used to 
map 3,270 markers to 3,021 unique positions with an average intermarker distance 
corresponding to ~1 Mb (Guyon et al. 2003). The 1 Mb RH map facilitated 
characterization of a more comprehensive screening set, the MSS-2, composed of 325 
microsatellite markers with an average spacing of 9 Mb (Guyon et al. 2003). 
Sequencing the canine genome  
The importance of the dog as a model for many human hereditary diseases is a 
major impetus for sequencing the canine genome. Celera (Rockville, MD) conducted the 
first large scale canine sequencing effort with DNA from a male Standard Poodle. 
Access to the sequence (coverage is 1X) is available through collaborations with The 
Institute for Genome Research. Work using this resource is currently underway and one 
aspect of this work is directed towards mapping independent gene sequences (Ostrander 
et al. 2002). This 1X sequence has considerable gaps and this was a factor in the 
decision by the National Institutes of Health to designate sequencing of the canine 
genome as a high priority (http://www.nih.gov/news/pr/sep2002/nhgri-12.htm). 
Sequencing began in June 2003 using DNA isolated from a female Boxer 
(http://www.genome.gov/11007358) and is being done at the Whitehead Genome Center 
in a manner similar to that utilized in sequencing of the murine genome. By utilizing 
different library sizes cloning bias will be minimized, thereby allowing a hierarchical 
approach for sequence assembly. This method will provide approximately 6-fold 
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sequence coverage and 50-fold physical coverage. Other sequencing efforts include end-
sequencing of clones retrieved from BAC libraries. More specifically, sequences have 
been obtained from approximately 1,500 BAC clones and 668 of these are mapped, 
yielding an initial framework for future mapping (Guyon et al. 2003). 
A second valuable resource for study of the canine genome is the development of 
a single nucleotide polymorphism (SNP) map. Recent results indicate that interbreed 
sequence comparisons are a reasonable strategy for identifying useful SNPs within many 
breeds (Brouillette and Venta 2002). Even so, it must be noted that a SNP map which 
will facilitate high throughput screening of the genome (10 Kb spacing) will require the 
identification of 250,000 SNPs (Ostrander et al. 2002). Additionally, efforts are being 
made to construct normalized or subtracted cDNA libraries, and to characterize 
expressed sequence tags (ESTs). McCombie and others (Table 8) maintain an interactive 
website for access to current canine EST projects (http://www.cshl.org/genbin/cgi-
bin/golden_retriever.cgi), listing several canine cDNA resources. Lastly, the canine 
genome sequencing efforts will be complemented by expression profiling in canine 
models of human diseases and such work is underway through various collaborations 
(http://crisp.cit.nih.gov/crisp). 
 
Canine diseases and genetic analyses 
As progress is made in constructing maps and sequencing of the canine genome, 
more mutation based and linkage based genetic tests will be developed to allow 
detection of deleterious alleles. While mutation based tests allow guaranteed results 
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because the specific mutation has been defined, linkage based tests do not provide such 
certainty due to recombination events that may cause false negative and positive results.  
 
Table 8. The canine genome and current resources for mapping. 
Chromosome number (2N) 78 
Genome size 2.8 x 109 bp 
Meiotic Linkage Map  
     Microsatellites 354 
1Radiation Hybrid Map  
     Microsatellites 1596 
     gene sequences + ESTs 900 
     BAC end sequences 668 
     Sequence tag sites (STS) 106 
2Integrated Linkage and RH Map  
    Common to cytogenetic and RH 102 
    Common to RH and meiotic linkage 251 
    Common to cytogenetic and meiotic linkage 52 
BAC library 8.1-fold coverage 
     1BAC end sequencing 1,504 
     1BAC end sequence containing microsatellites 39 
3ESTs 19465 
2SNPs 78 
2STS 200 
1Numbers reflect those reported in 2003 (Guyon et al.), and discovery of SNPs, STSs, and BAC end sequences 
continues in numerous laboratories. 
2As reported by FHCRC, http://www.fhcrc.org/science/dog_genome/dog.html. 
3EST development is ongoing and referenced number is current as of submission date, with R. McCombie and A. 
George having submitted the majority of EST sequences to GenBank. 
 
Candidate gene analyses 
The candidate gene approach uses analysis of pedigrees and phenotypes together 
with comparisons of analogous diseases in other species to identify candidate genes that 
may be responsible for a given disease. An excellent example of this is the identification 
of the gene causative for autosomal dominant progressive retinal atrophy in the English 
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Mastiff. After determining the mode of inheritance by controlled outcross matings, Kijas 
and coworkers (2003) selected three genes responsible for approximately half of all 
human autosomal dominant retinal disease (http://www.sph.uth.tmc.edu/Retnet) for 
evaluation in the dog. Their analysis revealed that the rhodopsin gene contained a 
transversion altering the protein’s amino acid sequence. Association testing followed, 
and confirmed that the rhodopsin mutation was responsible for this form of progressive 
retinal atrophy in the English Mastiff. 
Another recent candidate gene investigation revealed the mutation responsible 
for XLAS in a group of mixed-breed dogs. Alport syndrome is a chronic, progressive 
glomerulonephritis characterized by ultrastructural changes in the glomerular basement 
membrane. The most common form of AS in the human is XLAS and is due to 
mutations in COL4A5 (Jais et al. 2000). A colony of mixed-breed dogs segregating 
naturally occurring XLAS was studied and found to exhibit clinical, 
immunohistological, and ultrastructural characteristics virtually identical to that seen in 
human XLAS (Lees et al. 1999). Therefore, full-length COL4A5 cDNAs from normal 
and affected dogs were sequenced. This work revealed a 10 bp deletion in exon 9, 
resulting in a frameshift which disrupts the collagenous region of the protein, causing a 
premature stop codon within exon 10. This study also led to development of a mutation 
based genetic test for XLAS (Cox et al. 2003b).  
Other candidate gene analyses include the study of dilated cardiomyopathy 
(DCM) in the Doberman Pinscher. DCM provides an example of the difficulties 
geneticists sometimes face in studying canine hereditary diseases. That is, DCM is a 
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lethal, late onset disease (average age of onset is approximately 6 years) and this 
complicates obtaining DNA samples for linkage analysis. The possibility of phenocopies 
adds to the difficulties in analysis. Furthermore, the mode of inheritance is uncertain 
although the likely presence of a founder effect suggests a major gene is necessary for a 
dog to be affected. Several DCM-causing genes have been identified in human families 
and are candidate genes for canine DCM. In the human, every gene identified to date 
accounts for a small proportion of heritable DCM, suggesting that any number of genes 
could be responsible for canine DCM (Schönberger and Seidman 2001). Progress is 
being made by eliminating many of these candidate genes as causative (e.g., Meurs et al. 
2001; Venta et al. unpublished results), but new approaches to identify genes for 
complex diseases are needed. 
Linkage analyses 
Linkage studies rely upon informative pedigrees that have affected and non-
affected individuals available for sampling. Generally, such extended pedigrees are not 
available or accessible for human studies, but are common in the dog. Another 
advantage of using the dog in genetic studies is that the problem of locus heterogeneity 
inherent to human linkage studies is reduced. This is due to founder effects and minimal 
genetic diversity in breeds that have arisen from small populations. 
Some conditions (e.g., deafness) are not amenable to the candidate gene 
approach since too many candidates exist. Thus, pedigree assembly for linkage analysis 
is necessary. While it is known that a relationship exists between hereditary hearing loss 
and pigmentation in the Dalmatian, the nature of this association is unclear. Even so, 
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candidate gene studies have eliminated a few genes such as PAX3 (Brenig et al. 2003), 
but the number of remaining candidate genes is quite large. Therefore, linkage analysis  
is being performed by Muhle et al. (2002) who have assembled a kindred of Swiss 
Dalmatians and Cargill et al. (personal communication), who have assembled a kindred 
of US Dalmatians. 
 The utility of linkage analysis is exemplified by the study of hereditary 
multifocal renal cystadenocarcinoma and nodular dermatofibrosis (RCND), a rare cancer 
in the German Shepherd Dog. RCND is a spontaneous, inherited disease with several 
human correlates, albeit none that match all facets of the disease exactly. Jonasdottir and 
colleagues (2000) propagated a colony segregating RCND and used the MSS-1 
screening panel for linkage analysis. One microsatellite marker yielded a lod score of 
16.7 and the RCND locus was mapped to canine chromosome 5. Within the targeted 
region are several attractive candidate genes and future work will likely identify the gene 
responsible for RCND. 
Linkage analysis is also being used to identify loci contributing to canine hip 
dysplasia (CHD). CHD is a degenerative disease, primarily in large breeds, that results 
in part, from increased joint laxity. Functional subluxation of the hip, poor hip joint 
congruity, and debilitating secondary osteoarthritis are hallmarks of CHD. Although the 
mode of inheritance is unknown, recent investigations offer heritability estimates 
ranging from 0.11 to 0.68 (Bliss et al. 2002). An outcrossed pedigree of Labrador 
Retrievers and Greyhounds has been constructed for use in linkage studies of CHD and 
is currently being analyzed by a genome-wide screen (Todhunter et al. 2003). 
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Linkage disequilibrium 
 Linkage disequilibrium (LD) mapping relies upon population based gene and 
marker frequencies considered to be in disequilibrium if the marker and allele do not 
assort independently within the population. In LD, the marker and allele segregate 
together at a greater frequency than would be expected by their individual frequencies. 
This type of association would be expected for genes and markers in a population with 
common ancestral origin. Many breeds are derived from very small founding 
populations and gene flow between breeds is restricted by registration requirements. 
Thus, LD is a valuable tool for identification of genes responsible for hereditary diseases 
and other traits of interest. 
 The dog is particularly well suited for LD analysis. For example, Ostrander and 
Kruglyak (2000) presented evidence for the utility of LD through analysis of cancers in 
the Golden Retriever. The estimated risk of malignancy for the Golden Retriever is 
significantly higher than that for other breeds (Priester and McKay 1980). If the genes 
for malignancy originated in a popular sire, LD would be expected over large distances 
(Ostrander et al. 2000). This phenomenon is not restricted to cancers or a specific breed 
but rather applies to other diseases with hereditary components and to those breeds for 
which founding history, litter sizes, etc. are well documented. For those populations in 
which such information can be gathered, it is estimated that LD will extend 5-10 cM 
from loci causative for diseases (Ostrander et al. 2001). Furthermore, calculations 
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estimate that screening of 10 affected individuals of a given breed has adequate power 
for detection of regions with genetic homogeneity through identity by descent, as would 
be expected within a single line of dogs. If, however, dogs from various breeding lines 
are needed, it is estimated that only 40 dogs would be necessary for screening based 
upon conditions of moderate heterogeneity (Houwen et al. 1994). In this case, it would 
be reasonable to assume dogs within a breed carry the same mutation due to a common 
ancestral origin; therefore, the overlap of genetic regions revealed by LD would narrow 
the genomic region containing the causative gene (Ostrander et al. 2000). 
A current study using LD concerns canine sebaceous adenitis (SA), an 
inflammatory disease of the skin characterized by hair loss and unpleasant odor, making 
affected animals far from desirable pets. SA is archetypical of a number of heritable 
canine dermatological diseases in that 1) there are a few breeds with high prevalence but 
many breeds have sporadic occurrence, 2) there often is an inability to definitively call a 
dog "normal" based on phenotype, 3) onset often occurs during maturity and 4) there are 
no plausible candidate genes. These findings preclude a candidate gene approach or 
traditional linkage studies. SA has been recognized in over 55 breeds and mongrels but 
the Standard Poodle and Akita have the highest prevalences. Analysis of both breeds 
suggests SA is an autosomal recessive trait. However, there are more normal dogs than 
expected for an autosomal recessive disease due to subclinically affected dogs and dogs 
with late-onset disease (Rosser et al. 1987; Dunstan and Hargis 1995; Reichler et al. 
2001; Scott et al. 2002). The Akita (rather than the Standard Poodle) is currently being 
studied by several groups pursuing association studies to define LD because SA in this 
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breed fits the criteria established in the human for using association studies (Kruglyak 
1997; Houwen et al. 1994; Elston 1998; De La Chapelle and Wright 1998). 
Future of Canine Genomics 
Clearly there has been an explosion in knowledge of canine genetics and the 
canine genome. This new information is augmenting studies of human hereditary 
diseases, comparative genomics and clinical veterinary medicine, yet the full impact of 
the new information remains to be seen. The primary benefits to be derived from study 
of canine genetics are 1) the addition of comparative genomic information regarding a 
species evolutionarily and physiologically closely related to the human, 2) a better 
understanding of canine hereditary diseases and subsequent elimination of many disease 
alleles from breeding populations and, 3) insight into analogous human hereditary 
diseases and implementation of therapies, including gene therapy protocols. The 
importance of the latter is illustrated by success in gene therapy for two different 
diseases. Firstly, gene therapy prevents clinical manifestations of a lysosomal storage 
disease in a canine model of the disease (Ponder et al. 2002). Secondly, a form of early 
childhood blindness, Leber congenital amaurosis, has been corrected by gene therapy in 
a spontaneous canine model of the disease (Acland et al. 2001). These examples and 
others are indicative of the power of the dog as a large animal model of human 
hereditary diseases. The similarity between orthologous canine and human genes ensures 
that analogous human disease genes will be identified. In conclusion, research in canine 
genetics and genomics is benefiting the human and the dog, our companion for many 
centuries. 
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CHAPTER VII 
SUMMARY 
 
Our laboratory studies the dog because of its intrinsic value to humans. While 
the direction of the laboratory has evolved and matured over the last four years, the 
goal is the same: we want to improve the health and quality of life for all dogs through 
increased understanding of canine genetics. The specific aims of our work are to 1) 
understand the genetics underlying hereditary diseases of the ear, kidney, pancreas and 
musculoskeleton, 2) contribute to increasing the density of the canine map by 
characterizing and mapping gene loci that are members of gene families and 3) to 
develop tools for more efficient analysis of the canine genome.  
Success in addressing these objectives is shown by the facts that our laboratory 
has identified the mutation causative for canine XLAS, the first discovery at Texas 
A&M University of a gene responsible for a disease of a companion animal (Cox et al. 
2003b), mapped many gene loci (Miller et al. 1999; Miller et al. 2001; Cox et al. 
2003a; Lowe et al. 2003; Tsai et al. 2004) and improved our ability to carry out 
genome-wide analyses of the dog (Yang et al. 1999; Cargill et al. 2002; Clark et al. 
2004), and been involved in the efforts to sequence the canine genome (Ostrander et al. 
2002). 
The impetus for work reported here is the diagnosis of AS in a family of mixed 
breed dogs (Lees et al. 1999). Renal failure is common in the dog and is a major cause 
of death.  Therefore, we are interested in understanding the genetics and 
pathophysiology of this disease in order to develop better diagnostic and treatment 
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regimens. Importantly, regardless of etiology, renal diseases reach a certain common 
point in the disease process (secondary renal disease). Thus, the NAV model of XLAS 
provides insight into ESRD in general.  That is, due to the reserve capacity of the 
kidney, most dogs with ESRD are not diagnosed until very late in the disease process 
(whatever its primary cause), when the majority of the renal capacity has been lost and 
damage to the kidney is irreversible.  Our colony is an  excellent model in which to 
follow the progression of ESRD from the very beginnings of disease. This being so, 
future studies in the laboratory will include a temporal study of global gene expression 
by microarray analysis and Q-T-PCR at various stages of the lives of NAV dogs.  It is 
hoped that this will allow for the identification of potential biomarkers and targets for 
therapeutic intervention. 
Chapter II describes the mapping of the type I and IV collagens. This increases 
the density of the map of the canine genome, and provides information pertaining to 
synteny and the conservation of sequence through evolution. COL1A1 maps to CFA9, 
and COL1A2 maps to CFA14, which match locations with their human orthologs.  The 
type IV collagens, as expected, form 3 separate linkage groups. COL4A1 and COL4A2 
map to CFA8, COL4A3 and COL4A4 map to CFA25, and COL4A5 and COL4A6 form 
their own linkage group with two microsattelite markers mapped to CFAX.  These 
results confirm the evolutionary relationship of type IV collagens in other species. It is 
believed that COL4A1 was the original type IV collagen, which by a duplication and 
inversion event, spawned COL4A2, in a head-to-head position.  The other four type IV 
collagens were duplications of COL4A1 and COL4A2.  COL4A1, COL4A3, and 
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COL4A5 are most similar to each other, and COL4A2, COL4A4, and COL4A6 are most 
similar.   
 Chapter III reports the fortuitous amplification of a cDNA encoding the renal-
specific glycoprotein uromodulin.  The umod gene is linked to CZP2 in an RH group 
not yet assigned to a chromosome, but is likely CFA6. This conclusion is based on the 
synteny between CFA6 and HSA16, to which these genes have been mapped in the 
human.  The function of umod is unknown, but sequencing of it is timely, given the 
recent discovery that mutations in the gene cause two hereditary diseases in the human.  
 Chapter IV reports the main focus of my doctoral work.  The clinical study of 
XLAS in NAV dogs has taken place over a number of years, but the sequencing of 
COL4A5, and identification of the mutation causative for the disease was necessary for 
the use of this colony as a true disease model for human XLAS.  The full-length 
sequence was generated in 13 overlapping fragments, and a 10 bp deletion was found 
in exon 9, resulting in a frameshift and premature stop codon in exon 10.  The severe 
clinical phenotype of the NAV dog is partially explained by the nature of this mutation 
(Gross et al. 2003).  After sequencing and identification of a mutation, an allele-
specific genetic test was also developed to allow easy identification of carrier females 
and of dogs destined to develop XLAS. 
 There is no satisfactory treatment for human or canine XLAS and the only 
alternatives are dialysis and/or renal transplantation.  Thus, our laboratory and others 
are exploring the possibility of gene transfer therapy as a treatment of AS. Introduction 
(and subsequent expression in the kidney) of the wild-type coding sequence to 
compensate for a defective type IV collagen might allow the GBM to form properly 
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thereby stabilizing or restoring GBM function. Theoretically, if gene transfer therapy 
were applied early in the disease process, progressive renal damage and failure might 
be prevented entirely. However, a prerequisite to trials in human patients is the 
development of the technology and demonstration of the safety and efficacy of gene 
transfer therapy in a suitable animal model (e.g., the dog) of AS.  Because of this, part 
of the future focus of work in our laboratory is on the generation of a full-length clone 
of COL4A5 for gene therapy studies, and the testing of this clone in the NAV dog as a 
proof-of-principle experiment for the development of the therapy for human use. 
The differential gene expression of kidneys from normal and affected XLAS 
NAV dogs is the focus of Chapter V.  Four affected dogs were used to assess gene 
expression in the end stage XLAS kidney as compared to three normal siblings.  Very 
little is known about the global gene expression differences at end-stage, and probing 
of canine-specific microarray revealed approximately 1,200 differentially expressed 
genes.  Trends of a subset of clinically interesting genes were confirmed by Q-RT-
PCR.  As expected, many genes playing important roles in maintenance and 
functioning of the extracellular matrix, cell structure, immune system, and signaling 
pathways were up-regulated in XLAS dogs.  Unfortunately, the type IV collagens did 
not hybridize well on the chip, and were therefore scrutinized by Q-RT-PCR as well.  
COL4A1 and COL4A2 were found to be moderately up-regulated (but not as much as 
COL1A1 and COL1A2), while the rest of the type IV collagens showed no statistically 
significant difference between normal and XLAS dogs.  This finding is in agreement 
with the literature for human XLAS but contradicts a study on the Samoyed model of 
XLAS, in which a down-regulation in COL4A3, COL4A4, and COL4A5 is reported 
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(Thorner et al. 1996) leading the authors to conclude that these genes may be co-
regulated pre-transcriptionally.  We see no evidence of such a finding or mechanism in 
our dogs. 
Chapter VI is a comprehensive review of the current status of canine genetics 
and genomics.  It highlights recent advances in the integration of a RH and linkage 
maps, allowing the development of a new microsatellite marker set, the MSS-2, for 
whole genome screens. The decision by the NIH to fund the sequencing of the dog 
demonstrates the importance of canine genetics to human medicine.  Equally important 
is that the sequence and the emerging comprehensive SNP map will eventually foster 
development of screening and testing for various hereditary diseases of the dog. 
 In conclusion, this work adds to knowledge of canine hereditary diseases and 
canine genomics by providing the foundation for gene therapy for AS. Also, the NAV 
dog is an excellent model for study of end stage renal failure in the dog and human.  
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